<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85595</article-id><article-id pub-id-type="doi">10.7554/eLife.85595</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Chromosomes and Gene Expression</subject></subj-group></article-categories><title-group><article-title>Inhibition of DNMT1 methyltransferase activity via glucose-regulated <italic>O</italic>-GlcNAcylation alters the epigenome</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-304240"><name><surname>Shin</surname><given-names>Heon</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5480-8492</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304241"><name><surname>Leung</surname><given-names>Amy</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304242"><name><surname>Costello</surname><given-names>Kevin R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-127924"><name><surname>Senapati</surname><given-names>Parijat</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7324-1230</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304243"><name><surname>Kato</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-325991"><name><surname>Moore</surname><given-names>Roger E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304244"><name><surname>Lee</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304245"><name><surname>Lin</surname><given-names>Dimitri</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304246"><name><surname>Tang</surname><given-names>Xiaofang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-189427"><name><surname>Pirrotte</surname><given-names>Patrick</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-205966"><name><surname>Bouman Chen</surname><given-names>Zhen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3291-1090</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-127965"><name><surname>Schones</surname><given-names>Dustin E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7692-8583</contrib-id><email>dschones@coh.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05fazth07</institution-id><institution>Department of Diabetes Complications and Metabolism, Beckman Research Institute, City of Hope</institution></institution-wrap><addr-line><named-content content-type="city">Duarte</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00w6g5w60</institution-id><institution>Irell and Manella Graduate School of Biological Sciences, City of Hope</institution></institution-wrap><addr-line><named-content content-type="city">Duarte</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Integrated Mass Spectrometry Shared Resource, City of Hope Comprehensive Cancer Center Duarte</institution><addr-line><named-content content-type="city">Duarte</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02hfpnk21</institution-id><institution>Cancer &amp; Cell Biology Division, Translational Genomics Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Phoenix</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>20</day><month>07</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85595</elocation-id><history><date date-type="received" iso-8601-date="2022-12-15"><day>15</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-07-19"><day>19</day><month>07</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-05-11"><day>11</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.11.491514"/></event></pub-history><permissions><copyright-statement>Â© 2023, Shin et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Shin et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85595-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85595-figures-v2.pdf"/><abstract><p>The DNA methyltransferase activity of DNMT1 is vital for genomic maintenance of DNA methylation. We report here that DNMT1 function is regulated by <italic>O</italic>-GlcNAcylation, a protein modification that is sensitive to glucose levels, and that elevated <italic>O</italic>-GlcNAcylation of DNMT1 from high glucose environment leads to alterations to the epigenome. Using mass spectrometry and complementary alanine mutation experiments, we identified S878 as the major residue that is <italic>O</italic>-GlcNAcylated on human DNMT1. Functional studies in human and mouse cells further revealed that <italic>O</italic>-GlcNAcylation of DNMT1-S878 results in an inhibition of methyltransferase activity, resulting in a general loss of DNA methylation that preferentially occurs at partially methylated domains (PMDs). This loss of methylation corresponds with an increase in DNA damage and apoptosis. These results establish <italic>O</italic>-GlcNAcylation of DNMT1 as a mechanism through which the epigenome is regulated by glucose metabolism and implicates a role for glycosylation of DNMT1 in metabolic diseases characterized by hyperglycemia.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>epigenetics</kwd><kwd>metabolism</kwd><kwd>O-GlcNAcylation</kwd><kwd>hyperglycemia</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd><italic>Mus Musculus</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01DK112041</award-id><principal-award-recipient><name><surname>Schones</surname><given-names>Dustin E</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01CA220693</award-id><principal-award-recipient><name><surname>Schones</surname><given-names>Dustin E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100017804</institution-id><institution>AR-DMRI City of Hope</institution></institution-wrap></funding-source><award-id>Pilot</award-id><principal-award-recipient><name><surname>Schones</surname><given-names>Dustin E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Extracellular glucose promotes <italic>O</italic>-GlcNAcylation of DNMT1 and inhibition of DNMT1 function in the maintenance of genomic methylation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Protein <italic>O</italic>-GlcNAcylation is a dynamic and reversible post-translational modification that attaches a single <italic>O</italic>-linked Î²-<italic>N</italic>-acetylglucosamine to serine or threonine residues (<xref ref-type="bibr" rid="bib25">Hart et al., 1996</xref>). It is modulated by two <italic>O</italic>-GlcNAc cycling enzymes, <italic>O</italic>-GlcNAc transferase (OGT) and <italic>O</italic>-GlcNAcase (OGA), that respond to metabolic signals (<xref ref-type="bibr" rid="bib26">Hart et al., 2007</xref>; <xref ref-type="bibr" rid="bib57">Slawson et al., 2010</xref>). Increased concentrations of UDP-GlcNAc that are observed in conditions of excess glucose lead to a general increase in protein <italic>O</italic>-GlcNAcylation (<xref ref-type="bibr" rid="bib67">Walgren et al., 2003</xref>). Obesogenic diets, furthermore, have elevated protein <italic>O</italic>-GlcNAcylation in various human cell types, including liver cells (<xref ref-type="bibr" rid="bib22">Guinez et al., 2011</xref>), lymphocytes (<xref ref-type="bibr" rid="bib62">Torres and Hart, 1984</xref>), and immune cells (<xref ref-type="bibr" rid="bib14">de Jesus et al., 2018</xref>).</p><p>As with other post-translational modifications, <italic>O</italic>-GlcNAcylation of proteins can influence the function and/or stability of the targeted proteins (<xref ref-type="bibr" rid="bib54">Shin et al., 2018</xref>; <xref ref-type="bibr" rid="bib72">Yang and Qian, 2017b</xref>). Thousands of proteins are targets for <italic>O</italic>-GlcNAcylation, including many epigenetic regulatory proteins. For example, the <italic>O</italic>-GlcNAcylation of TET family proteins alters their activity, localization, and targeting (<xref ref-type="bibr" rid="bib12">Chen et al., 2013</xref>; <xref ref-type="bibr" rid="bib29">Ito et al., 2014</xref>; <xref ref-type="bibr" rid="bib53">Shi et al., 2013</xref>; <xref ref-type="bibr" rid="bib77">Zhang et al., 2014</xref>). While all DNA methyltransferases have been shown to be <italic>O</italic>-GlcNAcylated (<xref ref-type="bibr" rid="bib8">Boulard et al., 2020</xref>), the functional consequences of this have not been previously investigated.</p><p>Among the DNA methyltransferase (DNMT) family of proteins, DNMT1 is imperative for maintaining DNA methylation patterns during replication (<xref ref-type="bibr" rid="bib7">Bestor and Ingram, 1983</xref>). DNMT1 is a modular protein with several domains necessary for interacting with cofactors, including the BAH1 and BAH2 domains (<xref ref-type="bibr" rid="bib43">Maresca et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Ren et al., 2018</xref>). The stability and function of DNMT1 have been shown to be regulated through post-translational modifications, including acetylation, phosphorylation, and methylation (<xref ref-type="bibr" rid="bib51">Scott et al., 2014</xref>).</p><p>Partially methylated domains (PMDs), large domains with a loss of DNA methylation, were originally identified in cultured cell lines (<xref ref-type="bibr" rid="bib40">Lister et al., 2009</xref>) and subsequently found to be a characteristic of cancer cells (<xref ref-type="bibr" rid="bib6">Berman et al., 2011</xref>; <xref ref-type="bibr" rid="bib10">Brinkman et al., 2019</xref>). PMDs have also been detected in non-cancerous healthy tissues, where they are associated with late replication loci (<xref ref-type="bibr" rid="bib23">Hansen et al., 2010</xref>; <xref ref-type="bibr" rid="bib79">Zhou et al., 2018</xref>). While PMDs are generally thought to arise from a lack of fidelity in maintenance methylation (<xref ref-type="bibr" rid="bib13">Decato et al., 2020</xref>), the mechanisms responsible for the establishment of PMDs have remained unclear. Here, we report that the activity of DNMT1 is regulated by extracellular levels of glucose through <italic>O</italic>-GlcNAcylation and is associated with loss of methylation within PMDs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>High glucose conditions increase <italic>O</italic>-GlcNAcylation of DNMT1</title><p>To validate that DNMT1 can be <italic>O</italic>-GlcNAcylated, we treated Hep3B cells with OSMI-4 (OSMI), an OGT inhibitor (<xref ref-type="bibr" rid="bib44">Martin et al., 2018</xref>), or with Thiamet-G (TMG), an OGA inhibitor (<xref ref-type="bibr" rid="bib17">Elbatrawy et al., 2020</xref>). As expected, immunoblots of cellular lysate with an antibody recognizing pan-<italic>O</italic>-GlcNAc (RL2) reveal that inhibition of OGA increased global levels of <italic>O</italic>-GlcNAc while inhibition of OGT decreased global levels of <italic>O</italic>-GlcNAc (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). To distinguish whether DNMT1 is <italic>O</italic>-GlcNAcylated, DNMT1 immunoprecipitation was performed with cellular lysates treated with OSMI or TMG. Immunoblots with <italic>O</italic>-GlcNAc antibodies revealed that TMG treatment increases <italic>O</italic>-GlcNAc of DNMT1 while OSMI treatment decreases <italic>O</italic>-GlcNAc (<xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). In addition to Hep3B cells, we found that DNMT1 is <italic>O</italic>-GlcNAcylated in HepG2 cells (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>) and B-cell-derived lymphocytes, indicating that DNMT1 is <italic>O</italic>-GlcNAcylated across various cell types (<xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>).</p><p>To assess the effect of increased glucose metabolism on <italic>O</italic>-GlcNAcylation of DNMT1, we treated Hep3B cells with normal or low concentrations of glucose (5 mM) or high glucose (25 mM) and examined global protein <italic>O</italic>-GlcNAcylation as well as the <italic>O</italic>-GlcNAcylation of DNMT1 specifically (<xref ref-type="bibr" rid="bib24">HardivillÃ© et al., 2020</xref>). Consistent with previous reports (<xref ref-type="bibr" rid="bib3">Andrews et al., 2000</xref>), the total amount of protein <italic>O</italic>-GlcNAcylation was increased with high glucose treatment (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Global protein <italic>O</italic>-GlcNAcylation was also induced with high concentrations of sucrose, albeit to a lower extent than with glucose (<xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>). To specifically assess the level of <italic>O</italic>-GlcNAcylated DNMT1, we performed immunoprecipitation of DNMT1 from lysates of glucose treated Hep3B cells and immunoblotted for <italic>O</italic>-GlcNAc. As with the analysis of total protein, high glucose treatment increased the <italic>O</italic>-GlcNAcylation of DNMT1 (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). High sucrose treatment also increased the <italic>O</italic>-GlcNAcylation of DNMT1 (<xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>). The increased <italic>O</italic>-GlcNAcylation of DNMT1 with high glucose and sucrose treatment was also observed in HepG2 cells (<xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>). The changes in <italic>O</italic>-GlcNAcylation of DNMT1 from glucose treatment were not influenced by alterations in the activity of OGT or OGA as we observed the enzymatic activity of OGT or OGA was not significantly changed by glucose treatment (<xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4</xref>), consistent with previous results (<xref ref-type="bibr" rid="bib52">Seo et al., 2016</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>High glucose increases <italic>O</italic>-GlcNAcylation of DNMT1 in cell lines and primary cells.</title><p>(<bold>A</bold>) Hep3B cells were treated with glucose (5 mM or 25 mM) with or without Thiamet-G (TMG). Shown are immunoblots of collected lysates using antibody targeting <italic>O</italic>-GlcNAc and GAPDH (n = 3). (<bold>B</bold>) Lysates of Hep3B treated with glucose were immunoprecipitated with DNMT1 and immunoprecipitates were immunoblotted with antibody targeting <italic>O</italic>-GlcNAc (n = 3). (<bold>C</bold>) Peripheral blood mononuclear cells (PBMCs) were isolated from three individual donor blood samples and treated with increasing concentration of glucose for 24 hr. Collected cell lysates from PBMCs were immunoprecipitated with antibody targeting DNMT1 and immunoblotted for <italic>O</italic>-GlcNAc. Representative blot from one donor (n = 3). (<bold>D</bold>) Immunoblots for <italic>O</italic>-GlcNAc and GAPDH from liver samples of C57BL/6J mice given a high-fat/high-sucrose diet (HF/HS) or normal diet (chow) for 4 mo, and immunoprecipitated with Dnmt1. Lysates of mouse liver were immunoprecipitated with Dnmt1 and immunoprecipitates were immunoblotted with antibody targeting <italic>O</italic>-GlcNAc. *p&lt;0.001; **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>A-D</bold>); ns, not significant; data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig1">Figure 1AâD</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>DNMT1 can be <italic>O</italic>-GlcNAcylated in Hep3B cells.</title><p>Hep3B cells were treated with Thiamet-G (TMG) or OSMI-4 (OSMI). Shown are representative immunoblots of treated Hep3B lysates performed with antibodies targeting <italic>O</italic>-GlcNAc and GAPDH and bar graphs of relative expression between <italic>O</italic>-GlcNAc compared to control, GAPDH (n = 3, experimental replicates). Lysates from treated Hep3B with glucose were immunoprecipitated with DNMT1 and immunoprecipitates were immunoblotted with antibody targeting <italic>O</italic>-GlcNAc (n = 3). ***p&lt;0.0001 by Studentâs <italic>t</italic>-test; Data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1âfigure supplement 1âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>DNMT1 can be <italic>O</italic>-GlcNAcylated in HepG2 cells and B-cells-derived lymphocytes.</title><p>(<bold>A</bold>) HepG2 cells were treated with Thiamet-G or OSMI. Shown are immunoblots of treated HepG2 lysates performed with immunoblots of immunoprecipitates performed with antibodies targeting <italic>O</italic>-GlcNAc (n = 3). (<bold>B</bold>) Shown are immunoblots of B cell and lymphocytes (LCL) lysates performed with immunoblots of immunoprecipitates performed with antibodies targeting <italic>O</italic>-GlcNAc (n = 3). **p&lt;0.0005, ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>A, B</bold>); data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig1s2sdata1"><label>Figure 1âfigure supplement 2âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig1-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 3.</label><caption><title>Global protein <italic>O</italic>-GlcNAcylation was induced with high concentrations of sucrose.</title><p>(<bold>A</bold>) Hep3B cells were treated with sucrose (5 mM or 25 mM). Shown are immunoblots of collected lysates using antibody targeting <italic>O</italic>-GlcNAc and GAPDH (n = 3). Lysates of Hep3B treated with sucrose were immunoprecipitated with DNMT1 and immunoprecipitates were immunoblotted with antibody targeting <italic>O</italic>-GlcNAc (n = 3). (<bold>B</bold>) HepG2 cells were treated with 5 mM glucose or sucrose, or 25 mM glucose or sucrose. Lysates of HepG2 treated with glucose were immunoprecipitated with DNMT1 and immunoprecipitates were immunoblotted with antibody targeting <italic>O</italic>-GlcNAc (n = 3). **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>A, B</bold>); data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig1s3sdata1"><label>Figure 1âfigure supplement 3âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3A and B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig1-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 4.</label><caption><title>The enzymatic activity of OGT or OGA was not significantly changed by glucose treatment.</title><p>(<bold>A</bold>) OGT activity was measured with low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc) using the UDP-Glo Glycosyltransferase activity kit (Promega) (n = 3). (<bold>B</bold>) OGA activity was measured with low (5 mM, CTRL) or high glucose with TMG (25 mM, <italic>O</italic>-GlcNAc) using the <italic>O</italic>-GlcNAcase (OGA, NAG, or MGEA5) assay kit (Biomedical Research Service &amp; Clinical Application) (n = 3). ns, not significant; data are represented as mean Â± SD from three replicates of each sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig1-figsupp4-v2.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 5.</label><caption><title>DNMT1 can be <italic>O</italic>-GlcNAcylated in primary cells (peripheral blood mononuclear cells [PBMCs]).</title><p>Pooled PBMCs treated with low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc) were immunoprecipitated with antibody targeting DNMT1 and immunoblotted for <italic>O</italic>-GlcNAc (n = 3). ***p&lt;0.0001 by Studentâs <italic>t</italic>-test; data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig1s5sdata1"><label>Figure 1âfigure supplement 5âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig1-figsupp5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig1-figsupp5-v2.tif"/></fig></fig-group><p>To examine whether an increase in <italic>O</italic>-GlcNAcylation of DNMT1 also occurs in primary cells, we collected peripheral blood mononuclear cells (PBMCs) from three separate patient donors and treated the PBMCs with increasing glucose levels (0 mM, 5 mM, 10 mM, 15 mM, and 20 mM). Consistent with our observations in Hep3B cells, we observed an increase in <italic>O</italic>-GlcNAcylation of DNMT1 with increased glucose levels (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Combining the high glucose condition with OGA inhibition by TMG resulted in a further increase in <italic>O</italic>-GlcNAcylation of DNMT1 (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s5">Figure 1âfigure supplement 5</xref>). To examine the relationship between glucose levels and the <italic>O</italic>-GlcNAcylation of DNMT1 in an in vivo context, we examined liver samples from C57BL/6J mice fed an obesogenic high-fat/high-sucrose (HF/HS) diet for 16 wk (<xref ref-type="bibr" rid="bib60">Tang et al., 2020</xref>; details in âMaterials and methodsâ). These samples displayed an increase in total <italic>O</italic>-GlcNAcylation in liver samples from HF/HS fed mice (<xref ref-type="fig" rid="fig1">Figure 1D</xref>) as well as increased <italic>O</italic>-GlcNAcylation of DNMT1 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). These data validate the <italic>O</italic>-GlcNAcylation of DNMT1 and that the degree of <italic>O</italic>-GlcNAcylation of DNMT1 increases with glucose concentrations.</p></sec><sec id="s2-2"><title>Identification of the major <italic>O</italic>-GlcNAcylation sites of DNMT1</title><p>To begin to identify the residue(s) <italic>O</italic>-GlcNAcylated on DNMT1, we utilized OGTSite (<xref ref-type="bibr" rid="bib31">Kao et al., 2015</xref>) to predict potential sites of <italic>O</italic>-GlcNAcylation. OGTSite, which uses experimentally verified <italic>O</italic>-GlcNAcylation sites to build models of substrate motifs, identified 16 candidate <italic>O</italic>-GlcNAc modified sites on human DNMT1 (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We next employed mass spectrometry analysis to examine the post-translational modifications on DMNT1 in Hep3B cells. We overexpressed DNMT1 using a Myc-tagged DNMT1 construct to increase the protein level of DNMT1 in Hep3B cells (<xref ref-type="bibr" rid="bib35">Li et al., 2006</xref>). Immunoblots with Myc antibody (<xref ref-type="bibr" rid="bib75">Yompakdee et al., 1996</xref>) revealed a band corresponding to Myc-DNMT1 in transfected, but not mock transfected, cells (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). We further confirmed with immunoprecipitation followed by immunoblot that the overexpressed Myc-DNMT1 can be <italic>O</italic>-GlcNAcylated (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). For mass spectrometry analysis, we treated Myc-DNMT1 expressing cells with 25 mM TMG to further increase the <italic>O</italic>-GlcNAcylation of DNMT1. Myc-DNMT1 was enriched from transfected cells by monoclonal Ab-crosslinked immunoprecipitation and subjected to in-solution digestion using three different enzymes (AspN, chymotrypsin, and LysC) and high-resolution LC-MS/MS analysis. Peptide analyses revealed that S878, which is located on the bromo-associated homology (BAH1) domain of DNMT1 is <italic>O</italic>-GlcNAcylated (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2</xref>, and <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Analysis of the evolutionary conservation of DNMT1 sequence (details in âMaterials and methodsâ) revealed that S878 is conserved through vertebrates to <italic>Arabidopsis thaliana</italic> (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Three previously unreported phosphorylated residues were also detected (T208, S209, and S1122) (<xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Identification of <italic>O</italic>-GlcNAcylated sites within DNMT1 by LC-MS/MS.</title><p>(<bold>A</bold>) Schematic drawing of the DNMT1 <italic>O</italic>-GlcNAc-modified region enriched from Hep3B cells based on mass spectrometry (MS) data and tandem MS (MS/MS) peaks. FTMS+ p NSI full MS (400.0000â1600.0000). DQDYARFESPPKTQPTEDNKF (S9 HexNAc) â S878. (<bold>B</bold>) Schematic diagram of identified novel <italic>O</italic>-GlcNAcylated and phosphorylated sites within DNMT1 as determined via LC-MS/MS. DMAP, DNA methyltransferase associated protein-binding domain; PCNA, proliferating cell nuclear antigen-binding domain; NLS, nuclear localization sequences; RFTS, replication foci targeting sequence domain; BAH, bromo-adjacent homology domain. (<bold>C</bold>) Sequence conservation of S878 in vertebrates. (<bold>D</bold>) Each immunoprecipitated Myc-DNMT1 wild type and substituted mutants was immunoblotted with an <italic>O</italic>-GlcNAc antibody (n = 3). **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>D</bold>); N.D., not detected, ns, not significant; data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Myc-DNMT1-WT in Hep3B cells can be <italic>O</italic>-GlcNAcylated.</title><p>Myc-DNMT1-WT were transfected into Hep3B cells. Shown are immunoblots of treated DNMT1-WT lysates performed with antibodies targeting Myc, DNMT1, Tubulin, H3, and <italic>O</italic>-GlcNAc (n = 3). Lysates from treated DNMT1-WT were immunoprecipitated with Myc antibody. Shown are immunoblots of immunoprecipitates performed with antibodies targeting <italic>O</italic>-GlcNAc and CBB stained gel (Coomassie Brilliant Blue stain).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2âfigure supplement 1âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>Tandem MS/MS peaks of <italic>O</italic>-GlcNAcylated DNMT1 peptides.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig2-figsupp2-v2.tif"/></fig></fig-group><p>We chose the three top candidates based on prediction score (T158, T616, and T882) as well as the site identified from mass spectrometry analysis (S878) for further analysis with alanine mutation experiments (<xref ref-type="bibr" rid="bib49">Rexach et al., 2012</xref>). The threonine/serine residues were mutated to alanine residues on the Myc-DNMT1 construct and <italic>O</italic>-GlcNAcylation was evaluated with immunoblot following immunoprecipitation. Loss of threonine and serine at positions T158 and S878 respectively resulted in a loss of <italic>O</italic>-GlcNAcylation, indicating that these two residues are required for <italic>O</italic>-GlcNAcylation, with the DNMT1-S878A and DNMT1-T158A/S878A mutant resulting in &gt;50% reduction of <italic>O</italic>-GlcNAcylation (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). These results indicate that T158 (near the PCNA binding domain) and S878 (within the BAH1 domain) are the <italic>O</italic>-GlcNAcylated residues of DNMT1.</p></sec><sec id="s2-3"><title><italic>O</italic>-GlcNAcylation of DNMT1 results in loss of DNA methyltransferase activity</title><p>The BAH domains of DNMT1 are known to be necessary for DNA methyltransferase activity (<xref ref-type="bibr" rid="bib21">Gong et al., 2021</xref>; <xref ref-type="bibr" rid="bib74">Yarychkivska et al., 2018</xref>). Given that S878 is in the BAH1 domain, we reasoned that <italic>O</italic>-GlcNAcylation of this residue could impact the DNA methyltransferase activity of DNMT1. To test this, we treated Hep3B and HepG2 cells with either low (5 mM, CTRL) or high glucose combined with TMG (25 mM, <italic>O</italic>-GlcNAc) and evaluated the DNA methyltransferase activity of immunoprecipitated DNMT1 with the EpiQuik DNMT Activity/Inhibition ELISA Easy Kit (P-3139, EpiGentek, details in âMaterials and methodsâ). Intriguingly, high glucose/TMG treatment reduced the activity of DNMT1 (<xref ref-type="fig" rid="fig3">Figure 3A</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Site-specific <italic>O</italic>-GlcNAcylation inhibits DNMT1 methyltransferase function.</title><p>For (<bold>AâD</bold>), bar graphs are of relative activity of DNA methyltransferase activity measured as absorbance from a DNMT activity/Inhibition ELISA kit and representative immunoblots of immunoprecipitates performed with antibodies targeting DNMT1. (<bold>A</bold>) Hep3B cells were treated with low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc) (n = 3). (<bold>B</bold>) Peripheral blood mononuclear cells (PBMCs) from donors were treated with increasing concentrations of glucose (range: 0â25 mM with TMG) (n = 3). (<bold>C</bold>) Liver samples from C57BL/6J mice given a high-fat/high-sucrose diet (HF/HS) or a normal diet (chow) for 4 mo. (<bold>D</bold>) Immunoprecipitated DNMT1 wild type and substituted mutants were treated with 5 mM or 25 mM glucose (n = 3). *p&lt;0.001; **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>AâD</bold>); ns, not significant; data are represented as mean Â± SD from three replicates of each sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>Site-specific <italic>O</italic>-GlcNAcylation at DNMT1 sites abrogate the function of methyltransferase and DNA loss of methylation at CpG island under high glucose/Thiamet-G (TMG) conditions.</title><p>(<bold>A</bold>) HepG2 cells were treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). Shown are absorbance of DNA methyltransferase activity performed with DNA methyltransferase activity kit (n = 3, technical replicates from three biological replicates for each strain). (<bold>B</bold>) Hep3B cells were treated with 25 mM glucose with or without Thiamet-G by time dependent. Shown are absorbance of DNA methyltransferase activity performed with DNA methyltransferase activity kit (n = 3, technical replicates from three biological replicates for each strain). **p&lt;0.0005, ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>A, B</bold>); data are represented as mean Â± SD from three replicates of each sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 2.</label><caption><title>The methylation loss by high glucose/Thiamet-G (TMG) conditions was not apparent in the DNMT1-S878A mutant.</title><p>(<bold>A</bold>) Each Hep3B and Myc-DNMT1-overexpressed mutant (DNMT1-WT or DNMT1-S878A) was treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc), 5-aza or GSK-3484862 (negative control). Shown are absorbance of global DNA methylation of LINE-1 performed with global DNA methylation LINE-1 kit (n = 3). (<bold>B</bold>) Each HepG2 and Myc-DNMT1-overexpressed mutants (DNMT1-WT or DNMT1-S878A) were treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). Shown are absorbance of global DNA methylation of LINE-1 performed with global DNA methylation LINE-1 kit (n = 3, technical replicates from three biological replicates for each strain). (<bold>C</bold>) DNA was extracted from Hep3B and Myc-DNMT1-overexpressed mutants (DNMT1-WT or DNMT1-S878A) were treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc) or 5-aza (negative control) with MspI (negative control) or HpaII. Shown are extracted genomic DNA samples and analyze on the 4200 TapeStation System with the Genomic DNA Screen Tape assay with methylation-sensitive enzyme using MspI or HpaII (n = 3, technical replicates from three biological replicates for each strain). **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>A, B</bold>); ns, not significant; data are represented as mean Â± SD from three replicates of each sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 3.</label><caption><title>High glucose/Thiamet-G (TMG) conditions do not impact localization of DNMT1-WT or DNMT1-S878A.</title><p>(<bold>A</bold>) Hep3B cells expressed with DNMT1-WT and DNMT1-S878 cells were treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). (<bold>B</bold>) HepG2 cells expressed with DNMT1-WT and DNMT1-S878 cells were treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). DNMT1 localization was determined by immunofluorescence using confocal microscopy.</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3âfigure supplement 3âsource data 1.</label><caption><title>Raw fluorescence image files of <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig3-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig3-figsupp3-v2.tif"/></fig></fig-group><p>We next examined the impact of glucose levels on the function of DNMT1 in primary cells by treating PBMCs with increasing concentrations of glucose (0 mM, 5 mM, 10 mM, 15 mM, 20 mM, and 25 mM with TMG) for 96 hr and measuring the DNA methyltransferase activity of DNMT1. We observed a striking dose-dependent inhibition of the DNA methyltransferase activity of DNMT1 (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Lastly, we examined the activity of DNMT1 in the liver samples of mice fed an HF/HS diet, which showed a decreased activity of DNMT1 (<xref ref-type="fig" rid="fig3">Figure 3C</xref>) compared to chow-fed mice. Together, these data indicate that elevated levels of extracellular glucose can inhibit the methyltransferase function of DNMT1.</p><p>We next examined the ability of the DNMT1 alanine mutants (DNMT1-T158A and DNMT1-S878A), which cannot be <italic>O</italic>-GlcNAcylated, to attenuate the impact of high glucose- and TMG-induced loss of DNA methyltransferase activity. Compared to the DNA methyltransferase activity of DNMT1-WT (Myc-DNMT1-WT), the DNA methyltransferase activity of DNMT1-S878A (Myc-DNMT1-S878A) is not inhibited by high glucose/TMG treatment (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), indicating that <italic>O</italic>-GlcNAcylation of DNMT1-S878 is directly involved in the inhibition of methyltransferase activity. In contrast, the DNA methyltransferase activity of DNMT1-T158A (Myc-DNMT1-T158A) is inhibited by high glucose/TMG treatment in a manner similar to DNMT1-WT (Myc-DNMT1-WT), indicating that <italic>O</italic>-GlcNAcylation of DNMT1-T158 does not affect its DNA methyltransferase activity (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p><p>A previous phospho-proteomic analysis revealed that DNMT1-S878 can be phosphorylated (<xref ref-type="bibr" rid="bib78">Zhou et al., 2013</xref>), but the functional consequences of this have not been investigated. To evaluate the potential that phosphorylation, rather than <italic>O</italic>-GlcNAcylation, of S878 is leading to the loss of DNA methyltransferase activity observed with the DNMT1-S878A mutant, we generated DNMT1-S878D mutant, a phosphomimetic mutant that cannot be <italic>O</italic>-GlcNAcylated and examined DNA methyltransferase activity in normal and high glucose/TMG conditions. With treatment this phospho-mimetic mutant did not have loss of DNA methyltransferase activity, indicating that <italic>O</italic>-GlcNAcylation of S878 but not phosphorylation of S878 is leading to loss of methyltransferase activity of DNMT1 (<xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p></sec><sec id="s2-4"><title><italic>O</italic>-GlcNAcylation of DNMT1 results in subsequent loss of DNA methylation</title><p>Given our observations that <italic>O</italic>-GlcNAcylation of DNMT1 inhibits its DNA methyltransferase activity, we reasoned that this would further result in a general loss of DNA methylation. To begin to assess this, DNA methylation was assayed using the global DNA methylation LINE-1 kit (Active Motif, details in âMaterials and methodsâ) as a proxy for global methylation. Comparison of DNA methylation under high glucose/TMG and treatment with DNA methylation inhibitors (5-aza or GSK-3484862 [<xref ref-type="bibr" rid="bib4">Azevedo Portilho et al., 2021</xref>]; details in âMaterials and methodsâ) revealed that treatment leads to a loss of DNA methylation in a manner comparable with a DNA methylation inhibitor, GSK-3484862 (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>). The methylation loss resulting from treatment with high glucose/TMG was not apparent in the DNMT1-S878A mutant, further demonstrating that <italic>O</italic>-GlcNAcylation of S878 within DNMT1 directly affects DNA methylation activity (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>). When we assessed methylation with the phosphor-mimetic mutant (DNMT1-S878D), there was no correlation between phosphorylation of DNMT1 S878 and DNA loss of methylation loss under high glucose/TMG conditions (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>). A complementary assessment of DNA methylation using methylation-sensitive restriction enzymes and gel electrophoresis (details in âMaterials and methodsâ) revealed similar trends of DNA methylation loss (<xref ref-type="fig" rid="fig3s2">Figure 3âfigure supplement 2</xref>) albeit to a lesser extent using HpaII digestion (vs. MseI in the LINE-1 assay kit). The differences can also be due to the variation between the two assays in enzyme activity/digestion and differences in hybridization vs. gel separation. To evaluate alterations to DNA methylation more precisely, we utilized direct sequencing of genomic DNA, which revealed an overall loss of DNA methylation across the genome.</p><p>To examine whether the genomic loss of DNA methylation under high glucose conditions is affected by changes in DNMT1 localization in the cell (<xref ref-type="bibr" rid="bib30">Jones et al., 2021</xref>), we examined changes in the cellular localization of DNMT1 by immunofluorescence. However, changes in DNMT1 under hyperglycemia do not appear to impact its nucleocytoplasmic localization (<xref ref-type="fig" rid="fig3s3">Figure 3âfigure supplement 3</xref>).</p></sec><sec id="s2-5"><title><italic>O</italic>-GlcNAcylation of DNMT1 results in loss of DNA methylation at PMDs</title><p>To more thoroughly examine the impact of high glucose-induced <italic>O</italic>-GlcNAcylation of DNMT1 on the epigenome, Myc-DNMT1-overexpressed cell lines (DNMT1-WT and DNMT1-S878A) were treated with either low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc) and DNA methylation was profiled with nanopore sequencing (ONT PromethION; details in âMaterials and methodsâ). A comparison of the methylation profiles in these cells revealed a global loss of methylation in high glucose compared to control (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). Conversely, for the DNMT1-S878A mutant, there was no appreciable decrease in DNA methylation by high glucose (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). These results collectively indicate that <italic>O</italic>-GlcNAcylation of S878 of DNMT1 leads to a global loss of DNA methylation.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>High glucose leads to loss of DNA methylation at cancer-specific partially methylated domains (PMDs).</title><p>(<bold>A</bold>) Density plot of DNA methylation for DNMT1-WT and DNMT1-S878A cells with either low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc). (<bold>B</bold>) Genome browser screenshot of DNA methylation for DNMT1-WT and DNMT1-S878A cells and low or high glucose along with liver tumor PMDs from <xref ref-type="bibr" rid="bib36">Li et al., 2016</xref>. (<bold>C</bold>) Boxplots of DNA methylation at PMDs or general genomic background (BG) for each DNMT1-WT and DNMT1-S878A treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). (<bold>D</bold>) Heatmap representation of global DNA methylation for DNMT1-WT and DNMT1-S878A cells under low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc) at gene-poor and gene-rich regions. (<bold>E</bold>) Methylation changes from <italic>O</italic>-GlcNAcylation of DNMT1 by wave score for replication timing (<xref ref-type="bibr" rid="bib23">Hansen et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Thurman et al., 2007</xref>). ***p&lt;0.0001 by Wilcoxon signed-rank test (<bold>C</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>DNA loss of methylation by increased global <italic>O</italic>-GlcNAcylation decreases.</title><p>Density plot of DNA methylation for DNMT1-WT and DNMT1-S878A cells with either low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc). (<bold>A</bold>) Partially methylated domain (PMD) regions, (<bold>B</bold>) non-PMD regions. (<bold>CâG</bold>) Bar graphs represent percentage of global DNA methylation of wild type and DNMT1 mutants (DNMT1-WT or DNMT1-S878A) that treated low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). (<bold>C</bold>) 5âUTR, (<bold>D</bold>) promoter, (<bold>E</bold>) gene body, (<bold>F</bold>) 3âUTR, and (<bold>G</bold>) intergenic regions. (<bold>H</bold>) Genome browser screenshot of DNA methylation data at a differentially methylated region by glucose concentration.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp1-v2.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 2.</label><caption><title>Global DNA methylation of wild type and DNMT1 mutants between low Fragments Per Kilobase of transcript per Million mapped reads (FPKM) regions and high FPKM regions (DNMT1-WT or DNMT1-S878A) that treated low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc) were determined by Nanopolish call methylation.</title><p>These are defined 'low FPKM' as containing &lt;25% of FPKM regions per Mb window and 'high FPKM' as containing &gt;75% of FPKM regions per Mb window.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp2-v2.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 3.</label><caption><title>Methylation changes from <italic>O</italic>-GlcNAcylation of DNMT1 in DNMT1-S878A mutant.</title><p>The loss of methylation was not observed in S878A mutant cells. (<bold>A, B</bold>) The distribution of each DNA methylation was divided by DNA replication timing.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp3-v2.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 4.</label><caption><title>DNA loss of methylation by increased global <italic>O</italic>-GlcNAcylation decreases around the transposable element (TE) regions.</title><p>(<bold>A</bold>) Boxplot represents the levels of DNA methylation on the TE regions or non-TE regions of each Myc-DNMT1-overexpressed mutants (DNMT1-WT or DNMT1-S878A) were treated with low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc). (<bold>BâD</bold>) Bar graphs represent percentage of global DNA methylation of wild type and DNMT1 mutants (DNMT1-WT or DNMT1-S878A) that treated low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). (<bold>B</bold>) SINE, (<bold>C</bold>) LINE, and (<bold>D</bold>) LTR regions. **p&lt;0.0005; ***p&lt;0.0001 by Wilcoxon signed-rank test (<bold>AâD</bold>); ns, not significant.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp4-v2.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 5.</label><caption><title>Loss of DNA methylation by increased global O-GlcNAcylation decreases.</title><p>Evolutionarily recent TEs are more likely to lose methylation than older elements in a variety of systems. Methylation percentages are shown around (<bold>A</bold>) LTR12C and (<bold>B</bold>) HERVH-int regions. The Myc-DNMT1 overexpressed mutants (DNMT1-WT or DNMT1-S878A) were treated low (5mM, CTRL) or high glucose/TMG (25mM, O-GlcNAc).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp5-v2.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 6.</label><caption><title>ZFP57 and ZNF605 demonstrate binding to a significant number of LTR12C elements present in liver cancer partially methylated domains (PMDs).</title><p>Genome browser screenshot of DNA methylation data LTR12C elements (blue) that demonstrate binding with ZFP57 and ZNF605 by glucose concentration.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp6-v2.tif"/></fig><fig id="fig4s7" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 7.</label><caption><title>Evolutionarily recent elements are less likely to lose methylation induced by <italic>O</italic>-GlcNAcylation of DNMT1.</title><p>The evolutionary distance between each group is from <xref ref-type="bibr" rid="bib47">Perelman et al., 2011</xref>. Boxplot represents the DNA methylation by clades of the human genome (<italic>Homo sapiens</italic> to <italic>Haplorhini</italic>). CTRL, control; <italic>O</italic>-Glc, <italic>O</italic>-GlcNAc.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp7-v2.tif"/></fig><fig id="fig4s8" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 8.</label><caption><title>Only loci with &gt;5Ã coverage were retained for analysis, comprising 90% of CpGs in the genome.</title><p>Shown are overall CpGs sites that detected with &gt;5Ã coverage DNA methylation analysis using Nanopore technology PromethION sequencer. Each condition is biologically replicated.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig4-figsupp8-v2.tif"/></fig></fig-group><p>Examination of DNA methylation changes induced by <italic>O</italic>-GlcNAcylation of DNMT1 revealed a preferential loss of DNA methylation at liver cancer PMDs (<xref ref-type="bibr" rid="bib36">Li et al., 2016</xref>) that was not observed in S878A mutant cells (<xref ref-type="fig" rid="fig4">Figure 4B and C</xref>). PMDs have several defining features, including being relatively gene poor and harboring mostly lowly transcribed genes (<xref ref-type="bibr" rid="bib13">Decato et al., 2020</xref>). We stratified the genome in terms of gene density and transcription rate (see âMaterials and methodsâ for details) and found that regions that lose methylation in high glucose conditions are largely gene-poor (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and contain lowly transcribed genes (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2</xref>; <xref ref-type="bibr" rid="bib11">Chang et al., 2014</xref>). PMDs have furthermore been linked to regions of late replication associated with the nuclear lamina (<xref ref-type="bibr" rid="bib10">Brinkman et al., 2019</xref>). We therefore examined the correlation between loss of methylation caused by high glucose and replication timing (<xref ref-type="bibr" rid="bib61">Thurman et al., 2007</xref>). In DNMT1-WT cells, late replication domains preferentially lose DNA methylation in high glucose/TMG conditions compared to early replication domains (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). This loss of methylation was not observed in DNMT1-S878A mutant cells (<xref ref-type="fig" rid="fig4s3">Figure 4âfigure supplement 3</xref>).</p></sec><sec id="s2-6"><title>Evolutionarily young TEs are protected from loss of methylation in high glucose conditions</title><p>One of the major functions of DNA methylation in mammalian genomes is the repression of repetitive elements (<xref ref-type="bibr" rid="bib16">Edwards et al., 2017</xref>). Furthermore, it has been shown that many chromatin proteins involved in the repression of TEs are capable of being <italic>O</italic>-GlcNAcylated (<xref ref-type="bibr" rid="bib8">Boulard et al., 2020</xref>). We therefore examined the potential of <italic>O</italic>-GlcNAcylation of DNMT1 to lead to loss of suppression of TEs. We found that high glucose conditions resulted in methylation loss at TEs in a manner similar to the nonrepetitive fraction of the genome (<xref ref-type="fig" rid="fig4s4">Figure 4âfigure supplement 4</xref>), with a more dramatic loss of methylation at LINEs and LTRs compared to SINE elements (<xref ref-type="fig" rid="fig4s4">Figure 4âfigure supplement 4</xref>). Given that evolutionarily recent TEs are more likely to lose methylation than older elements in a variety of systems (<xref ref-type="bibr" rid="bib2">Almeida et al., 2022</xref>; <xref ref-type="bibr" rid="bib80">Zhou et al., 2020</xref>), we examined the methylation status of two younger subfamilies, LTR12C (<italic>Hominoidea</italic>) and HERVH-int (<italic>Catarrhini</italic>) elements (<xref ref-type="fig" rid="fig4s5">Figure 4âfigure supplement 5</xref>). While HERVH-int elements show a loss of methylation similar to the rest of the genome, LTR12C elements do not lose methylation in the same manner (<xref ref-type="fig" rid="fig4s5">Figure 4âfigure supplement 5</xref>), suggesting that they are protected from the loss of methylation. To identify the possible regulatory mechanisms behind the continued maintenance of methylation of LTR12C elements, we examined binding data (ChIP-exo) of KRAB-associated zinc-finger proteins (<xref ref-type="bibr" rid="bib28">Imbeault et al., 2017</xref>), a family of proteins associated with the regulation of transposons, on all LTR12Cs present within hepatic cancer PMDs (<xref ref-type="bibr" rid="bib36">Li et al., 2016</xref>). ZFP57 and ZNF605 demonstrate binding to a significant number of LTR12C elements present in liver cancer PMDs (<xref ref-type="fig" rid="fig4s6">Figure 4âfigure supplement 6</xref>), suggesting that binding of these KZFPs could maintain the methylation at LTR12Cs. Stratifying all TEs by evolutionary age (<xref ref-type="bibr" rid="bib59">Storer et al., 2021</xref>) and examining the methylation changes induced by <italic>O</italic>-GlcNAcylation of DNMT1 for each clade revealed that evolutionarily recent elements in general are less likely to lose methylation than older elements (<xref ref-type="fig" rid="fig4s7">Figure 4âfigure supplement 7</xref>).</p></sec><sec id="s2-7"><title>Methylation changes at promoter regions of apoptosis and oxidative stress response genes upon inhibition of DNMT1</title><p>To further examine the impact of the altered epigenome in high glucose conditions, we examined the methylation levels of promoter regions (defined as the 2 kb window upstream and downstream of the transcription start site [TSS]) (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>). Hypermethylated (gain of methylation) and hypomethylated (loss of methylation) genes were classified as genes with differentially methylated regions overlapping the promoters (<xref ref-type="fig" rid="fig5s1">Figure 5âfigure supplement 1</xref>). Pathway analysis (see âMaterials and methodsâ for details) revealed that genes with hypomethylated promoters are involved in apoptosis and oxidative stress response pathways (<xref ref-type="fig" rid="fig5s2">Figure 5âfigure supplement 2</xref>). Examination of apoptosis-related proteins using an apoptosis proteome array revealed that apoptosis agonist proteins (cleaved-caspase3 and phopho-p53 [S15]) are increased and antagonistic proteins (pro-caspase3, surviving, and claspin) are decreased by high glucose treatment (<xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3</xref>). Intriguingly, only cIAP-1 is increased in the high glucose-treated DNMT1-S878A mutant cells (<xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3</xref>).</p></sec><sec id="s2-8"><title>DNA hypomethylation induced DNA damage and triggers apoptosis by high glucose</title><p>High glucose-induced generation of reactive oxygen species (ROS) has been shown to result in increased cell death (<xref ref-type="bibr" rid="bib1">Allen et al., 2005</xref>). Increased ROS has furthermore been shown to result in upregulation of DNMT1 (<xref ref-type="bibr" rid="bib27">He et al., 2012</xref>; <xref ref-type="bibr" rid="bib46">OâHagan et al., 2011</xref>). To further explore the link between glucose levels, DNMT1, and cell death, we treated DNMT1-WT and DNMT1-S878A cells with either low or high glucose/TMG for 96 hr and examined the fluorescence of 2â²,7â²-dichlorofluorescein diacetate (DCFH-DA) as an indicator for ROS (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The levels of ROS were increased upon treatment with 25 mM glucose with TMG in both DNMT1-WT and DNMT1-S878A (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Given that high levels of ROS can lead to increased DNA damage and subsequent cell death (<xref ref-type="bibr" rid="bib50">Rowe et al., 2008</xref>), we analyzed DNA damage using quantitative fluorescence image of Î³-H2A.X in DNMT1-WT and DNMT1-S878A cells and low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). Interestingly, DNA damage indicated by levels of Î³-H2A.X was reduced in high glucose/TMG-treated DNMT1-S878A cells compared to WT cells despite high ROS levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). To further confirm that this damage is from oxidative stress, we analyzed 8-hydroxy-2âdeoxyguanosine (8-OHdG) as a marker for oxidative DNA damage using EpiQuik 8-OhdG DNA damage quantification kit (EpiGentek, details in âMaterials and mmethodsâ). This also reduced DNA oxidative damage in high glucose-treated DNMT1-S878A cells compared to WT cells (<xref ref-type="fig" rid="fig5s4">Figure 5âfigure supplement 4</xref>). Furthermore, DNA damage induced by low glucose with GSK-3484862 treatment suggests that DNA hypomethylation is associated with increased DNA damage (<xref ref-type="fig" rid="fig5s4">Figure 5âfigure supplement 4</xref>; <xref ref-type="bibr" rid="bib4">Azevedo Portilho et al., 2021</xref>). Finally, examination of propidium iodide (PI) levels revealed that cell death was prominently increased in the high glucose-treated DNMT1-WT cells but suppressed in the DNMT1-S878A mutants (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Taken together, these results suggest that ROS-induced DNA damage under hyperglycemic conditions is partially mitigated by DNA methylation; elevated <italic>O</italic>-GlcNAcylation of DNMT1 coinciding with DNA methylation loss is associated with more ROS-induced DNA damage and increased cell death. These results indicate that extracellular metabolic stress and cell fate are linked through epigenetic regulation.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>High glucose-induced reactive oxygen species (ROS) and DNA damage cause apoptotic cell death in DNMT1-WT cells.</title><p>(<bold>A</bold>) Quantitative fluorescence image of ROS in DNMT1-WT and DNMT1-S878A cells with either low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc). (<bold>B</bold>) Quantitative fluorescence image of Î³-H2A.X in DNMT1-WT and DNMT1-S878A cells treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). (<bold>C</bold>) Quantitative fluorescence image of cell death in propidium iodide staining of DNMT1-WT and DNMT1-S878A cells under low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc). *p&lt;0.001; **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test (<bold>AâC</bold>); data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5âsource data 1.</label><caption><title>Raw fluorescence image files of <xref ref-type="fig" rid="fig5">Figure 5AâC</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 1.</label><caption><title>Heatmap representation of promoter DNA methylation for DNMT1-WT and DNMT1-S878A cells under low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc) at gene-poor and gene-rich regions.</title><p>(<bold>A</bold>) Whole promoters and (<bold>B</bold>) differentially methylated promoters.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 2.</label><caption><title>DNA loss of methylation within promoter region by increased global <italic>O</italic>-GlcNAcylation impact different gene pathways.</title><p>(<bold>A</bold>) Gene Ontology of the top 11 pathways of hypomethylated promoter DNA by high glucose treatment. (<bold>B</bold>) Gene interaction map of hypomethylated promoter DNA of DNMT1-WT by high glucose treatment.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig5-figsupp2-v2.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 3.</label><caption><title>Quantitative analysis of human apoptosis related proteins in DNMT1-WT and DNMT1-S878A with either low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc) using Proteome profiler (n = 3).</title><p>PC, positive control; NC, negative control; 1. cleaved-caspase3; 2, cIAP1; 3, claspin; 4, phospho-p53(S15); 5, survivin. ***p&lt;0.0001 by Studentâs <italic>t</italic>-test; Data are represented as mean Â± SD from three replicates of each sample.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5âfigure supplement 3âsource data 1.</label><caption><title>Uncropped blot files of <xref ref-type="fig" rid="fig5s3">Figure 5âfigure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-85595-fig5-figsupp3-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig5-figsupp3-v2.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5âfigure supplement 4.</label><caption><title>Each Hep3B (Mock) and Myc-DNMT1-overexpressed mutant (DNMT1-WT or DNMT1-S878A) was treated with low (5 mM, CTRL) or high glucose/Thiamet-G (TMG) (25 mM, <italic>O</italic>-GlcNAc), 5-aza, or GSK-3484862 (negative control).</title><p>Shown are absorbance of 8-OHdG performed with DNA damage quantification kit (n = 3). **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test; ns, not significant; data are represented as mean Â± SD from three replicates of each sample.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85595-fig5-figsupp4-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Although there is a great deal of evidence regarding the important regulatory role of <italic>O</italic>-GlcNAcylation in gene regulation (<xref ref-type="bibr" rid="bib9">Brimble et al., 2010</xref>), a direct link with maintenance of DNA methylation has not previously been established. The maintenance methyltransferase DNMT1 is essential for faithful maintenance of genomic methylation patterns and mutations in DNMT1, particularly in the BAH domains, lead to disruption of DNA methylation (<xref ref-type="bibr" rid="bib21">Gong et al., 2021</xref>; <xref ref-type="bibr" rid="bib74">Yarychkivska et al., 2018</xref>). The function of the Bromo-Adjacent Homology (BAH) domain is to mediate association of DNMT1 with replication foci during S phase to maintain methylation. The BAH-deleted form of DNMT1 was unable to maintain DNA methylation genome-wide or in IAP retrotransposons and major satellite DNA, commonly densely methylated sequences (<xref ref-type="bibr" rid="bib74">Yarychkivska et al., 2018</xref>). In addition, the DNMT1 S878F mutation results in hypomethylation of the HBG promoter region (<xref ref-type="bibr" rid="bib21">Gong et al., 2021</xref>). While it has been shown that DNMT1 can be <italic>O</italic>-GlcNAcylated (<xref ref-type="bibr" rid="bib8">Boulard et al., 2020</xref>), the site of <italic>O</italic>-GlcNAc modification on DNMT1 â as well as the functional consequences of this modification â has not previously been examined. In this study, we detected <italic>O</italic>-GlcNAcylation in the BAH1 domain of DNMT1 under high glucose/TMG conditions in cultured cells lines as well as in primary human and mouse cells. In addition, it was confirmed that the DNA methyltransferase activity of DNMT1 was directly inhibited by <italic>O</italic>-GlcNAcylation. Our findings suggest that the direct <italic>O</italic>-GlcNAcylation of DNMT1 disrupts the BAH1 domain, thereby suppressing the function of DNMT1. Therefore, this study provides novel insights into the mechanism of <italic>O</italic>-GlcNAcylation-mediated regulation of DNMT1 and global DNA methylation. Further studies are needed to clarify the molecular mechanism by which <italic>O</italic>-GlcNAcylation disrupts the BAH1 domains and regulates DNMT1 and DNA methylation.</p><p>Our results reveal that <italic>O</italic>-GlcNAcylation of DNMT1 impacts its DNA methyltransferase activity and affects DNMT1 function, leading to loss of DNA methylation at PMDs. PMDs have been observed in both healthy and disease cells and have been suggested to be associated with mitotic dysfunction. However, models for how these domains are established remain incomplete (<xref ref-type="bibr" rid="bib13">Decato et al., 2020</xref>). The results presented here suggest an additional layer whereby <italic>O</italic>-GlcNAcylation of DNMT1 at S878 due to increased glucose levels can inhibit the function of DNA methyltransferase activity of DNMT1, resulting in loss of methylation and establishment of PMDs.</p><p>High glucose conditions have previously been reported to lead to an increase in nuclear 25-hydroxycholesterol, which induces lipid accumulation and activates DNMT1 (<xref ref-type="bibr" rid="bib1">Allen et al., 2005</xref>; <xref ref-type="bibr" rid="bib68">Wang et al., 2020</xref>). Our results are consistent with the activity of DNMT1 gradually increasing with glucose concentrations (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>). This trend is reversed, however, upon TMG treatment (<xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>), suggesting that the increased activity of DNMT1 associated with glucose treatment is directly inhibited by <italic>O</italic>-GlcNAcylation within DNMT1.</p><p>Protein <italic>O</italic>-GlcNAcylation has recently been explored in the context of various diseases, including cancer, diabetes, and neurological diseases. Dysregulation of <italic>O</italic>-GlcNAcylation, driven by increased blood glucose levels in diabetes (<xref ref-type="bibr" rid="bib39">Ling and RÃ¶nn, 2019</xref>) or the Warburg effect in cancer cells, has been shown to play a crucial role in disease progression (<xref ref-type="bibr" rid="bib38">Liberti and Locasale, 2016</xref>; <xref ref-type="bibr" rid="bib65">Vander Heiden et al., 2009</xref>), which results in an increase in intracellular protein <italic>O</italic>-GlcNAcylation (<xref ref-type="bibr" rid="bib26">Hart et al., 2007</xref>; <xref ref-type="bibr" rid="bib25">Hart et al., 1996</xref>). <italic>O</italic>-GlcNAcylation acts as a molecular switch that can modulate protein function in response to nutrient changes and serve as a molecular sensor for specific cellular signals (<xref ref-type="bibr" rid="bib64">Vaidyanathan et al., 2014</xref>; <xref ref-type="bibr" rid="bib71">Yang et al., 2017a</xref>). Perturbations in the activity of <italic>O</italic>-GlcNAc transferase (OGT) and <italic>O</italic>-GlcNAcase (OGA) enzymes (<xref ref-type="bibr" rid="bib69">Wells et al., 2001</xref>; <xref ref-type="bibr" rid="bib76">Zhang et al., 2003</xref>), as well as alterations in posttranslational modifications, can disrupt protein functions vital for cell survival and contribute to metabolic reprogramming (<xref ref-type="bibr" rid="bib54">Shin et al., 2018</xref>; <xref ref-type="bibr" rid="bib70">Yang et al., 2006</xref>). The increased levels of <italic>O</italic>-GlcNAcylation observed in most diabetic patients and tumors (<xref ref-type="bibr" rid="bib15">de Queiroz et al., 2014</xref>) suggest its potential utility as a biomarker. By comparing the degree of protein glycosylation in specific diseases, such as diabetes or tumors (<xref ref-type="bibr" rid="bib42">Lu et al., 2022</xref>), with that in healthy cells, <italic>O</italic>-GlcNAcylation could potentially serve as a valuable diagnostic tool. Moreover, targeting <italic>O</italic>-GlcNAc-modified proteins with antibody-based therapeutics holds promise for cancer treatment and suppression of diabetic complications. By inducing tumor cell necrosis or inhibiting the abnormal activity associated with diabetic complications, these approaches represent innovative avenues for disease management. Our study highlights the impact of <italic>O</italic>-GlcNAcylation on DNA methyltransferase 1 (DNMT1), revealing its role in modulating DNA methylation. <italic>O</italic>-GlcNAcylation of DNMT1 impairs its methyltransferase function, leading to global loss of DNA methylation and aberrant activity of transposable elements. Targeting this aberrant modification with antibody therapeutics presents an exciting opportunity to restore normal DNA methylation patterns and mitigate disease complications. Continued research in this area will unveil the full potential of <italic>O</italic>-GlcNAcylation as a versatile tool in disease diagnosis and therapeutic interventions.</p><p>Metabolic diseases such as obesity and diabetes have been linked to epigenetic changes that alter gene regulation (<xref ref-type="bibr" rid="bib39">Ling and RÃ¶nn, 2019</xref>). It has previously been established that there is a general increase in protein <italic>O</italic>-GlcNAcylation in hyperglycemia conditions (<xref ref-type="bibr" rid="bib66">Vasconcelos-Dos-Santos et al., 2018</xref>) and several epigenetic regulatory factors have been shown to have increased <italic>O</italic>-GlcNAcylation under high glucose conditions (<xref ref-type="bibr" rid="bib5">Bauer et al., 2015</xref>; <xref ref-type="bibr" rid="bib18">Etchegaray and Mostoslavsky, 2016</xref>; <xref ref-type="bibr" rid="bib73">Yang et al., 2020</xref>). Our findings that extracellular glucose promotes <italic>O</italic>-GlcNAcylation of DNMT1 and inhibition of DNMT1âs function in maintenance of genomic methylation provide direct evidence that extracellular levels of glucose impacts epigenomic regulation.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene<break/>(<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom"><italic>DNMT1</italic></td><td align="left" valign="bottom">HUGO Gene Nomenclature Committee</td><td align="left" valign="bottom">HGNC:2976</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Hep 3B2.1â7</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HB-8064</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Cell line<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">Hep G2</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HB-8065</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Transfected construct<break/>(<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">pcDNA3/Myc-DNMT1</td><td align="left" valign="bottom">Addgene</td><td align="left" valign="bottom">Plasmid #36939</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-beta-actin (D6A8)<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 8457</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-alpha-tubulin (11H10)<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat# 2125</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-DNMT1 (60B1220.1)<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">Cat# NB100-56519</td><td align="left" valign="bottom">IP (1:250)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-DNMT1 (H-12)<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-271729</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-gamma H2A.X<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab11174</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH<break/>(rabbit monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab181602</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-H3<break/>(rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab1791</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Myc [Myc.A7]<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab18185</td><td align="left" valign="bottom">IP (1:250)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-<italic>O</italic>-GlcNAc (RL2)<break/>(mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab2739</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Aoat anti-rabbit IgG H&amp;L (HRP)<break/>(goat polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab6721</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG H&amp;L (HRP)<break/>(goat polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab6789</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-mouse IgG (H+L), Alexa 488<break/>(goat polyclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# A32723</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-T158A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">agccccaggatt CGA aggaaaagcacc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-T158A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ggtgcttttcct TCG aatcctggggct</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-T616A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">gacaggggaccc GCG aaagccaccacc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-T616A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ggtggtggcttt CGC gggtcccctgtc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-S878A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">gcgagattcgag GAG cctccaaaaacc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-S878A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ggtttttggagg CTC ctcgaatctcgc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-S878D</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">gcgagattcgag GAC cctccaaaaacc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-S878D</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ggtttttggagg GTC ctcgaatctcgc</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-T882A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">tcccctccaaaa GCC cagccaacagag</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">DNMT1-T882A</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">PCR primers</td><td align="left" valign="bottom">ctctgttggctg GGC ttttggagggga</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Q5 Site-Directed Mutagenesis kit</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E0554S</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EpiQuik DNMT Activity/Inhibition ELISA Easy Kit</td><td align="left" valign="bottom">EpiGentek</td><td align="left" valign="bottom">Cat# P-3139</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Global DNA methylation LINE-1</td><td align="left" valign="bottom">Active Motif</td><td align="left" valign="bottom">Cat# 55017</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">EpiQuik 8-OHdG DNA Damage Quantification Direct kit</td><td align="left" valign="bottom">EpiGentek</td><td align="left" valign="bottom">Cat# P-6003</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">OSMI-4</td><td align="left" valign="bottom">Selleck Chem</td><td align="left" valign="bottom">Cat# S8910</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Thiamet-G (TMG)</td><td align="left" valign="bottom">Cayman Chemical</td><td align="left" valign="bottom">Cat# 13237</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">bedGraphToBigWig</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib32">Kent et al., 2010</xref></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Clustal Omega</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib56">Sievers et al., 2011</xref></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Version 1.2.4</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">GraphPad Prism 9</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Version: 9.3.1</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Minimap2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib37">Li and Birol, 2018</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018550">SCR_018550</ext-link></td><td align="left" valign="bottom">Version: 2.17</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Nanopolish</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib41">Loman et al., 2015</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016157">SCR_016157</ext-link></td><td align="left" valign="bottom">Version: 0.11.1</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Python</td><td align="left" valign="bottom">Python Core Team</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version: 3.8.2</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">R</td><td align="left" valign="bottom">R Core Team</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Version: 3.4.3</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Samtools</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Lister et al., 2009</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002105">SCR_002105</ext-link></td><td align="left" valign="bottom">Version: 1.10</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">UniProt</td><td align="left" valign="bottom">The UniProt Consortium</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">Database of protein information (<ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/">https://www.uniprot.org/</ext-link>)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DAPI stain</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">D1306</td><td align="left" valign="bottom">1 Âµg/ml; marker for nuclear DNA</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Cell culture and plasmid DNA transfection</title><p>Human hepatocellular carcinoma cell lines Hep3B (HB-8064) and HepG2 (HB-8065) were purchased from ATCC (Manassas, VA). These cells were authenticated by ATCC with STR Profiling Results. All cell lines were shown to be negative in mycoplasma test using MycoScope (MY01050, Genlantis, San Diego, CA). The following ATCC-specified cell culture media were used: Dulbeccoâs modified Eagleâs medium (DMEM, 11885-084, Gibco, Grand Island, NY) or high glucose DMEM (11995-065, Gibco) with 10% fetal bovine serum (FBS, SH30910.03, HyClone, South Logan, UT) and Opti-MEM (1869048, Gibco). All cells were cultured at 37Â°C with a 5% CO<sub>2</sub> atmosphere incubator. HepG2 and Hep3B cells were transiently transfected (with the pcDNA3 with or without DNMT1 cDNA) using Lipofectamine 3000 (Invitrogen, Carlsbad, CA) and selected with Geneticin (G418, 10131-035, Gibco) according to the manufacturerâs instructions. Human DNMT1 plasmid was purchased from Addgene (#36939, Watertown, MA; <xref ref-type="bibr" rid="bib35">Li et al., 2006</xref>).</p></sec><sec id="s4-2"><title>Glucose-stress experimental conditions</title><p>Cell culture medium (DMEM) was replaced every 24 hr with low or high glucose. The glucose stress durations of the experiment were either 24 hr or 96 hr. Low glucose medium contains 5 mM glucose (normal physiological glucose level), whereas high glucose medium contains 25 mM glucose (hyperglycemic range &gt;7 mM) and corresponds to severe diabetes (<xref ref-type="bibr" rid="bib33">Koobotse et al., 2020</xref>). Thiamet-G (#13237, Cayman Chemical, Ann Arbor, MI) was added directly to the cell culture medium.</p></sec><sec id="s4-3"><title>Isolation of PBMCs</title><p>Blood samples from deidentified healthy donors were obtained following guidelines at the City of Hope as previously described (<xref ref-type="bibr" rid="bib34">Leung et al., 2018</xref>). PBMCs were isolated directly from human whole blood using Ficoll-Paque (Premium, GE Healthcare, Chicago, IL) density gradient centrifugation. 15 ml whole blood was mixed with same volume of phosphate-buffered saline containing 0.1% FBS +2 mM EDTA (PBS solution). Next, the blood mix was placed on top of 15 ml Ficoll and centrifuged at 400 Ã <italic>g</italic> to 200 Ã <italic>g</italic> for 40 min without brake. Next, remove the supernatant and wash three times with PBS solution.</p></sec><sec id="s4-4"><title>Isolation of B cells and EpsteinâBarr virus (EBV) infection for lymphocyte transformation</title><p>CD19<sup>+</sup> B cells were isolated from PBMCs using Dynabeads CD19<sup>+</sup> pan B (11143D, Invitrogen) according to the manufacturerâs instructions. 2.5 Ã 10<sup>8</sup> cells of PBMCs were resuspended in 10 ml isolation buffer (PBS, 0.1% BSA, 2 mM EDTA). 250 Î¼l of prewashed beads were added to PBMCs and incubated for 20 min in 4Â°C with gentle rotation. For positive isolation of CD19<sup>+</sup> B cells, beads and supernatant were separated using magnet, and supernatant was discarded. Beads were washed three times, and beads bounded with CD19<sup>+</sup> B cells were resuspended with 2.5 ml of cell culture medium (80% RPMI 1640, 20% heat-inactivated FBS, glutamine). CD19<sup>+</sup> B cells were released from Dynabeads using DETACHaBEAD (Invitrogen, ca12506D) according to the manufacturerâs instruction.</p><p>B cells were infected with EBV to transform lymphocytes. 10 ml of B cells were transferred into a T75 flask. 1.5 ml of stock EBV collected from a B95-8 strain-containing marmoset cell line and 1 ml of phytohemagglutinin P (PHA-P) were added to flask and incubated in 37Â°C with a 5% CO<sub>2</sub> atmosphere incubator. Every 5â7 d, 10 ml of cell culture medium was added. Cells were let to grow in the CO<sub>2</sub> atmosphere incubator for 30 d until all B cells were transformed to LCLs.</p></sec><sec id="s4-5"><title>Mouse liver samples</title><p>All animal experiments conducted have been approved by the Institutional Animal Care and Use Committees at City of Hope. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#17010). C57BL/6J mice were randomized to receive irradiated HF/HS diet (D12266Bi, Research Diets Inc, 17% kcal protein, 32% kcal fat, 51% kcal carbohydrate) starting at 8 weeks old for 16 wk. Mice on chow diet (D12489Bi, Research Diets Inc, 16.4% kcal protein, 70.8% kcal carbohydrate, 4.6% kcal fat) were fed for the same duration. To reduce blood contamination, mice were washed 10Ã with phosphate-buffered saline (PBS) solution. Washed liver tissues (two chow and two HF/HS) were cut into several pieces and divided into three groups each (three sets per each condition, total 12 samples). Each group of washed liver tissues were lysed with non-detergent IP buffer in the presence of a protease inhibitor (Cat# 8340; Sigma-Aldrich) and a phosphatase inhibitor cocktail (Cat# 5870; Cell Signaling) for the western blotting or immunoprecipitation. An increase in fasting blood glucose levels due to the HF/HS diet has been previously reported (<xref ref-type="bibr" rid="bib20">Franson et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Tang et al., 2020</xref>). At the end points, mice were euthanized with CO<sub>2</sub> inhalation.</p></sec><sec id="s4-6"><title>Immunoprecipitation and western blot analysis</title><p>Cell lysates were incubated with specific antibodies and lysis buffer for 4 hr. Subsequently, 30 Î¼l of washed Dynabeads (14311D, Thermo Fisher, Waltham, MA) were added to each lysate and incubated overnight at 4Â°C. Next, the beads were washed five times, and the antigens were eluted twice using 8 M urea buffer (8 M urea, 20 mM Tris pH 7.5, and 100 mM NaCl) and concentrated. The resulting samples were separated by Mini-PROTEAN TGX (4â20%, 4561093, Bio-Rad Laboratories, Hercules, CA) and transferred onto nitrocellulose membranes (Amersham Hybond, 10600021, GE Healthcare) using Trans-Blot SD Semi-dry Transfer Cell system (Bio-Rad Laboratories). The membranes were then blocked with 5% skim milk in Tris-buffered saline + Tween-20 (TBS-T; 20 mM Tris, 137 mM NaCl, 0.1% Tween-20, pH 7.6), incubated overnight at 4Â°C with a 1:1000 dilution of each antibody, and subsequently incubated for 1 hr with a 1:5000 dilution of a horseradish peroxidaseâconjugated goat anti-mouse secondary antibody (ab6789, Abcam, Cambridge, UK) or goat anti-rabbit secondary antibody (ab6721, Abcam). Immunoreactive proteins were detected using SuperSignal West Dura Extended Duration Substrate (34076, Thermo, Rockford, IL) and detected using a ChemiDoc MP Imaging system (Bio-Rad Laboratories). The band intensity was densitometrically evaluated using Image Lab software (version 5.2, Bio-Rad Laboratories).</p></sec><sec id="s4-7"><title>Protein identification using the Thermo Fusion Lumos system LC-MS/MS</title><p>Recombinant DNMT1 protein (30 mg) was reduced with dithiothreitol and alkylated with iodoacetamide. To ensure coverage of the predicted <italic>O</italic>-GlcNAc site, the protein was separately digested with three complementary enzymes (Chymotrypsin, AspN, and LysC). Digested peptides were desalted using C<sub>18</sub> stage tips (Pierce, Rockford, IL). LC-MS/MS analysis was performed on an Thermo Orbitrap Fusion Lumos system (Thermo Scientific, San Jose, CA). Peptides were separated on an Ultimate 3000 (Thermo Scientific) operated in nanoflow (300 nl/mi) mode using a 60 min LC gradient and an EasySpray column (2 Âµm particle sizes: 500 mm Ã 75 Î¼m I.D.). Full MS scans were acquired from 400 to 1600 <italic>m/z</italic> at 120,000 resolutions. MS/MS spectra were acquired at a resolution of 30,000 using HCD at 35% collision energy.</p><p>Raw data files were submitted to Byonic (v2.16.11) for target decoy search against the human protein database (<xref ref-type="bibr" rid="bib63">UniProt, 2023</xref>) assuming static Cys carbamidomethylation and dynamic Met oxidation, Ser/Thr GlcNAc, and Ser/Thr phosphorylation. Only peptides passing the false discovery rate threshold 0.01 were considered for downstream analysis. The sample was bracketed by <italic>Escherichia coli</italic> QC runs, which were then correlated to ensure instrument quality. QC passed threshold (â¥0.9) with an <italic>R</italic><sup>2</sup> of 0.98 (correlation value, <italic>R</italic> = 0.99).</p></sec><sec id="s4-8"><title>Conservation of DNMT1 sequence</title><p>The evolutionary conservation of DNMT1 was assessed via multiple sequence alignment with Clustal Omega (<xref ref-type="bibr" rid="bib56">Sievers et al., 2011</xref>). DNMT1 sequences for <italic>Homo sapiens</italic>, <italic>Mus musculus</italic>, <italic>Rattus norvegicus</italic>, <italic>Bos taurus</italic>, <italic>Gallus gallus,</italic> and <italic>Arabidopsis thaliana</italic> were obtained from <xref ref-type="bibr" rid="bib63">UniProt, 2023</xref> and aligned with Clustal Omega using default parameters.</p></sec><sec id="s4-9"><title>Site-directed point mutation</title><p>Specific primers for serine (S) and threonine (T) to alanine (A) and aspartic acid (D) mutations of DNMT1 were designed and used to site-directed point mutations in a plasmid vector. A recombinant DNA pcDNA3/Myc-DNMT1 was a gift from Arthur Riggs (Addgene plasmid #36939 Watertown, MA; <xref ref-type="bibr" rid="bib35">Li et al., 2006</xref>). A PCR-amplified DNA fragment of pcDNA3-DNMT1 was generated using Q5 Site-Directed Mutagenesis Kit (E0554S, NEB, Ipswich, MA). The primers used in this process are described in Supporting Information. After PCR, the non-mutated sequences were cleaved using Q5 KLD enzyme (New England Biolabs, Ipswich, MA) according to the manufacturerâs instructions. The mutated vectors were transformed into <italic>E. coli</italic> competent cells (NEB 5-alpha, New England Biolabs) that were cultured and prepared using a GenElute HP Plasmid Midi kit (NA0200-1KT, Sigma-Aldrich, St. Louis, MO).</p></sec><sec id="s4-10"><title>DNA methyltransferase activity assay</title><p>DNA methyltransferase activities of endogenous DNMT1 and recombinant DNMT1 were measured by EpiQuik DNMT Activity/Inhibition ELISA Easy Kit (P-3139, EpiGentek, Farmingdale, NY) according to the manufacturerâs instructions. DNMT1 methylates DNA substrates by transferring a methyl group from AdoMet to cytosine, and the methylated DNA can be captured by anti-5-mC antibodies. The endogenous DNMT1 (by anti-DNMT1 Ab, 60B1220.1) and recombinant DNMT1 (by anti-Myc, ab18185) were enriched using immunoprecipitation from each cell or tissue lysates. DNMT1s were isolated and normalized by BCA analysis. The activity of 5 ng DNMT1 was analyzed by 450 nm ELISA with an optimal wavelength of 655 nm in a microplate spectrophotometer. The activity of the DNMT enzyme is proportional to the measured optical density intensity.</p></sec><sec id="s4-11"><title>Global DNA methylation LINE-1 assay</title><p>Global DNA methylation of LINE-1 elements was measured via kit (Active Motif, Cat #55017, Carlsbad, CA) according to the manufacturerâs instructions. Hep3B and Myc-DNMT1-overexpressed mutants (DNMT1-WT or DNMT1-S878A) were treated with 5 mM glucose or 25 mM glucose, and 5-aza or GSK-3484862 (negative control). The activity of 100 ng was analyzed by 450 nm ELISA with an optimal wavelength of 655 nm.</p></sec><sec id="s4-12"><title>Agilent 4200 TapeStation</title><p>Global DNA methylation were measured by Agilent 4200 TapeStation system (Santa Clara, CA) with the Genomic DNA ScreenTape (5064-5365) and Genomic DNA Reagent (5067-5366) according to the manufacturerâs instructions. Hep3B and Myc-DNMT1-overexpressed mutants (DNMT1-WT or DNMT1-S878A) were treated with 5 mM glucose or 25 mM glucose and 5-aza (negative control).</p></sec><sec id="s4-13"><title>Nanopore PromethION sequencing</title><p>Genomic DNA was isolated from DNMT1-WT or DNMT1-S878A cells treated with low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc) using the QIAGEN DNA Mini Kit (13323, QIAGEN) with Genomic-tip (10223, QIAGEN) according to the manufacturerâs instructions. Sequencing libraries were prepared using the Ligation Sequencing Kit (SQK-LSK109, Oxford Nanopore Technologies) according to the manufacturerâs instructions. Sequencing was performed on a PromethION (Oxford Nanopore Technologies). Data indexing was performed using Nanopolish (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016157">SCR_016157</ext-link>). Reads were aligned using minimap2 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_018550">SCR_018550</ext-link>) with the following parameters: -a -x map-ont (<xref ref-type="bibr" rid="bib37">Li and Birol, 2018</xref>). Methylation state of CpGs was called using Nanopolish (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016157">SCR_016157</ext-link>) with the options call-methylation -t 8 (<xref ref-type="bibr" rid="bib41">Loman et al., 2015</xref>). Only loci with &gt;5Ã coverage were retained for analysis, comprising 90% of CpGs in the genome (<xref ref-type="fig" rid="fig4s8">Figure 4âfigure supplement 8</xref>). Methylation percentage was averaged across CpG islands.</p></sec><sec id="s4-14"><title>Determination of gene-poor or gene-rich regions and FPKM</title><p>Hep3B RNA-seq data were obtained from <xref ref-type="bibr" rid="bib11">Chang et al., 2014</xref>. Fastq files were aligned using HISAT2 version 2.1.0 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_015530">SCR_015530</ext-link>) to the hg19 genome. Duplications were removed using picard version 2.10.1 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006525">SCR_006525</ext-link>). Aligned reads were sorted using samtools version 1.10 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_002105">SCR_002105</ext-link>). UCSC genome browser tracks were established using bedGraphToBigWig. Fragments Per Kilobase of transcript per Million mapped reads (FPKM) were calculated using StringTie version 1.3.4d (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016323">SCR_016323</ext-link>).</p><p>For all datasets, Bedgraph files were generated using bedtools version 2.29.0 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006646">SCR_006646</ext-link>). BigWigs were generated using the UCSCtools bedGraphToBigWig. Heatmaps of global DNA methylation for DNMT1-WT and DNMT1-S878A cells under low or high glucose were generated using a custom script to profile the read coverage at each base and were visualized using pheatmap version 1.0.12 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016418">SCR_016418</ext-link>). All other heatmaps and aggregate plots were generated using deeptools (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_016366">SCR_016366</ext-link>).</p></sec><sec id="s4-15"><title>Measurement of ROS and PI staining</title><p>DNMT1-WT and DNMT1-S878A cells were seeded into 12-well plates with 5 mM or 25 mM glucose and TMG. The medium in each well was replaced with HBSS with 10 Î¼M DCF-DA (2â²,7â²-dichlorofluorescein diacetate; D6883, Abcam) or PI staining solution (P4864, Abcam). The fluorescence was filtered with fluorescein isothiocyanate (FITC) for ROS or Texas Red for PI staining (<xref ref-type="bibr" rid="bib55">Shin et al., 2020</xref>). Averages of fluorescence were analyzed using Olympus Cellsens software.</p></sec><sec id="s4-16"><title>DNA damage analysis</title><p>DNA damage was analyzed with Î³-H2A.X in DNMT1-WT and DNMT1-S878A cells and low (5 mM, CTRL) or high glucose/TMG (25 mM, <italic>O</italic>-GlcNAc) by immunofluorescence and using the EpiQuik 8-OHdG DNA Damage Quantification Direct Kit (P-6003, EpiGentek) according to the manufacturerâs protocol. The activity of 200 ng DNA was analyzed with a 450 nm absorbance microplate reader.</p></sec><sec id="s4-17"><title>Apoptosis array analysis</title><p>Apoptosis-related proteins were analyzed using Proteome profiler human apoptosis array kit (ARY009, R&amp;D Systems) according to the manufacturerâs protocol. The spots were detected using a ChemiDoc MP Imaging system (Bio-Rad Laboratories; <xref ref-type="bibr" rid="bib45">Na et al., 2020</xref>). The band intensity was densitometrically evaluated using Image Lab software (version 5.2, Bio-Rad Laboratories).</p></sec><sec id="s4-18"><title>KZFP binding in PMD-associated LTR12Cs</title><p>A list of PMDs in Hep3B cells were obtained from <xref ref-type="bibr" rid="bib36">Li et al., 2016</xref>. A full list of LTR12Cs was generated from filtering RepeatMasker (<xref ref-type="bibr" rid="bib58">Smit et al., 2013</xref>). The PMD-associated LTR12Cs were found using bedtools version 2.29.0 (RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:SCR_006646">SCR_006646</ext-link>). Putative KZFP regulators of LTR12Cs were determined using the consensus sequence of LTR12Cs and ChIP-exo from the Imbeault and Trono studies (<xref ref-type="bibr" rid="bib28">Imbeault et al., 2017</xref>) on the UCSC Repeat Browser (<xref ref-type="bibr" rid="bib19">Fernandes et al., 2020</xref>). PMD-associated LTR12Cs were then aligned again with peak files containing the ChIP-exo data to acquire a list of PMD-associated LTR12Cs with KZFP binding. Significant binding was defined as &gt;5 sequences bound as most LTR12Cs demonstrated very minimal KZFP binding (&lt;1 sequence bound). These were verified with Repeat Browser (<xref ref-type="bibr" rid="bib19">Fernandes et al., 2020</xref>).</p></sec><sec id="s4-19"><title>Quantification and statistical analysis</title><p>Statistical analyses were performed and graphed using GraphPad Prism 9 (v9.3.1). All statistical tests were performed by three independent biological replicate experiments assay, and the data are presented as means Â± standard deviations. *p&lt;0.001; **p&lt;0.0005; ***p&lt;0.0001 by Studentâs <italic>t</italic>-test; ns, not significant; data are represented as mean Â± SD.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Methodology, Writing - review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con11"><p>Resources</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments conducted have been approved by the Institutional Animal Care and Use Committees at City of Hope. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#17010).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Prediction of <italic>O</italic>-GlcNAcylated sites within DNMT1 using OGTSite.</title></caption><media xlink:href="elife-85595-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of total identified proteins.</title></caption><media xlink:href="elife-85595-supp2-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of post-translational modification (PTM) sites of human DNMT1.</title></caption><media xlink:href="elife-85595-supp3-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4.</label><caption><title>List of deposited data in this study.</title></caption><media xlink:href="elife-85595-supp4-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85595-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>PromethION sequencing data have been deposited in the NCBI Gene Expression Omnibus (GEO) and Sequence Read Archive (SRA) under accession no. GSE201470. Mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the data set identifier PXD043031.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Schones</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Inhibition of DNMT1 methyltransferase activity via glucose-regulated O-GlcNAcylation alters the epigenome</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE201470">GSE201470</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Schones</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>Inhibition of DNMT1 methyltransferase activity via glucose-regulated O-GlcNAcylation alters the epigenome</data-title><source>PRIDE</source><pub-id pub-id-type="accession" xlink:href="https://www.ebi.ac.uk/pride/archive/projects/PXD043031">PXD043031</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Salz</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE70091">GSE70091</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><data-title>mRNA and RNC-mRNA deep sequencing of three hepatocellular carcinoma cell lines</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49994">GSE49994</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This article is dedicated to the memory of Dr. Arthur Riggs. This work was supported by the National Institutes of Health, grants R01DK112041 and R01CA220693 (DES), as well as a pilot award from the Arthur Riggs Diabetes &amp; Metabolism Research Institute (DES). Research reported in this publication included work performed in the Pathology, Integrated Mass Spectrometry, and Integrative Genomics Shared Resources of the City of Hope, and was supported by the City of Hope CCSG Pilot award from the National Cancer Institute of the National Institutes of Health under award number P30CA033572.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>DA</given-names></name><name><surname>Yaqoob</surname><given-names>MM</given-names></name><name><surname>Harwood</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mechanisms of high glucose-induced apoptosis and its relationship to diabetic complications</article-title><source>The Journal of Nutritional Biochemistry</source><volume>16</volume><fpage>705</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2005.06.007</pub-id><pub-id pub-id-type="pmid">16169208</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida</surname><given-names>MV</given-names></name><name><surname>Vernaz</surname><given-names>G</given-names></name><name><surname>Putman</surname><given-names>ALK</given-names></name><name><surname>Miska</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Taming transposable elements in vertebrates: from epigenetic silencing to domestication</article-title><source>Trends in Genetics</source><volume>38</volume><fpage>529</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2022.02.009</pub-id><pub-id pub-id-type="pmid">35307201</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>SR</given-names></name><name><surname>Charnock</surname><given-names>SJ</given-names></name><name><surname>Lakey</surname><given-names>JH</given-names></name><name><surname>Davies</surname><given-names>GJ</given-names></name><name><surname>Claeyssens</surname><given-names>M</given-names></name><name><surname>Nerinckx</surname><given-names>W</given-names></name><name><surname>Underwood</surname><given-names>M</given-names></name><name><surname>Sinnott</surname><given-names>ML</given-names></name><name><surname>Warren</surname><given-names>RA</given-names></name><name><surname>Gilbert</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Substrate specificity in glycoside hydrolase family 10. Tyrosine 87 and leucine 314 play a pivotal role in discriminating between glucose and xylose binding in the proximal active site of Pseudomonas cellulosa xylanase 10A</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>23027</fpage><lpage>23033</lpage><pub-id pub-id-type="doi">10.1074/jbc.M000128200</pub-id><pub-id pub-id-type="pmid">10767281</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azevedo Portilho</surname><given-names>N</given-names></name><name><surname>Saini</surname><given-names>D</given-names></name><name><surname>Hossain</surname><given-names>I</given-names></name><name><surname>Sirois</surname><given-names>J</given-names></name><name><surname>Moraes</surname><given-names>C</given-names></name><name><surname>Pastor</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The DNMT1 inhibitor GSK-3484862 mediates global demethylation in murine embryonic stem cells</article-title><source>Epigenetics &amp; Chromatin</source><volume>14</volume><elocation-id>56</elocation-id><pub-id pub-id-type="doi">10.1186/s13072-021-00429-0</pub-id><pub-id pub-id-type="pmid">34906184</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>C</given-names></name><name><surname>GÃ¶bel</surname><given-names>K</given-names></name><name><surname>Nagaraj</surname><given-names>N</given-names></name><name><surname>Colantuoni</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>MÃ¼ller</surname><given-names>U</given-names></name><name><surname>Kremmer</surname><given-names>E</given-names></name><name><surname>Rottach</surname><given-names>A</given-names></name><name><surname>Leonhardt</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Phosphorylation of TET proteins is regulated via O-GlcNAcylation by the O-linked N-acetylglucosamine transferase (OGT)</article-title><source>The Journal of Biological Chemistry</source><volume>290</volume><fpage>4801</fpage><lpage>4812</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.605881</pub-id><pub-id pub-id-type="pmid">25568311</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>BP</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Aman</surname><given-names>JF</given-names></name><name><surname>Hinoue</surname><given-names>T</given-names></name><name><surname>Ramjan</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Noushmehr</surname><given-names>H</given-names></name><name><surname>Lange</surname><given-names>CPE</given-names></name><name><surname>van Dijk</surname><given-names>CM</given-names></name><name><surname>Tollenaar</surname><given-names>R</given-names></name><name><surname>Van Den Berg</surname><given-names>D</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains</article-title><source>Nature Genetics</source><volume>44</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1038/ng.969</pub-id><pub-id pub-id-type="pmid">22120008</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bestor</surname><given-names>TH</given-names></name><name><surname>Ingram</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA</article-title><source>PNAS</source><volume>80</volume><fpage>5559</fpage><lpage>5563</lpage><pub-id pub-id-type="doi">10.1073/pnas.80.18.5559</pub-id><pub-id pub-id-type="pmid">6577443</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulard</surname><given-names>M</given-names></name><name><surname>Rucli</surname><given-names>S</given-names></name><name><surname>Edwards</surname><given-names>JR</given-names></name><name><surname>Bestor</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Methylation-directed glycosylation of chromatin factors represses retrotransposon promoters</article-title><source>PNAS</source><volume>117</volume><fpage>14292</fpage><lpage>14298</lpage><pub-id pub-id-type="doi">10.1073/pnas.1912074117</pub-id><pub-id pub-id-type="pmid">32522876</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Brimble</surname><given-names>S</given-names></name><name><surname>Wollaston-Hayden</surname><given-names>EE</given-names></name><name><surname>Teo</surname><given-names>CF</given-names></name><name><surname>Morris</surname><given-names>AC</given-names></name><name><surname>Wells</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><source>Current Signal Transduction Therapy</source><publisher-name>Bentham science</publisher-name><pub-id pub-id-type="doi">10.2174/157436210790226465</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkman</surname><given-names>AB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Simmer</surname><given-names>F</given-names></name><name><surname>RodrÃ­guez-GonzÃ¡lez</surname><given-names>FG</given-names></name><name><surname>Smid</surname><given-names>M</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Glodzik</surname><given-names>D</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Staaf</surname><given-names>J</given-names></name><name><surname>RingnÃ©r</surname><given-names>M</given-names></name><name><surname>Sieuwerts</surname><given-names>A</given-names></name><name><surname>Ferrari</surname><given-names>A</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Fleischer</surname><given-names>T</given-names></name><name><surname>Kristensen</surname><given-names>V</given-names></name><name><surname>Gut</surname><given-names>M</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>BÃ¸rresen-Dale</surname><given-names>AL</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Gut</surname><given-names>IG</given-names></name><name><surname>Martens</surname><given-names>JWM</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1749</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09828-0</pub-id><pub-id pub-id-type="pmid">30988298</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Zi</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name><name><surname>Fan</surname><given-names>F</given-names></name><name><surname>Qin</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Su</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Ying</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhong</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Hou</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>He</surname><given-names>QY</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Systematic analyses of the transcriptome, translatome, and proteome provide a global view and potential strategy for the C-HPP</article-title><source>Journal of Proteome Research</source><volume>13</volume><fpage>38</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1021/pr4009018</pub-id><pub-id pub-id-type="pmid">24256510</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Bian</surname><given-names>C</given-names></name><name><surname>Fujiki</surname><given-names>R</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TET2 promotes histone O-GlcNAcylation during gene transcription</article-title><source>Nature</source><volume>493</volume><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/nature11742</pub-id><pub-id pub-id-type="pmid">23222540</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decato</surname><given-names>BE</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>X</given-names></name><name><surname>Wagenblast</surname><given-names>E</given-names></name><name><surname>Knott</surname><given-names>SRV</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name><name><surname>Smith</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Characterization of universal features of partially methylated domains across tissues and species</article-title><source>Epigenetics &amp; Chromatin</source><volume>13</volume><elocation-id>39</elocation-id><pub-id pub-id-type="doi">10.1186/s13072-020-00363-7</pub-id><pub-id pub-id-type="pmid">33008446</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jesus</surname><given-names>T</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Ramakrishnan</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Too sweet to resist: Control of immune cell function by O-GlcNAcylation</article-title><source>Cellular Immunology</source><volume>333</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2018.05.010</pub-id><pub-id pub-id-type="pmid">29887419</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Queiroz</surname><given-names>RM</given-names></name><name><surname>Carvalho</surname><given-names>E</given-names></name><name><surname>Dias</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>O-GlcNAcylation: The Sweet Side of the Cancer</article-title><source>Frontiers in Oncology</source><volume>4</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2014.00132</pub-id><pub-id pub-id-type="pmid">24918087</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>JR</given-names></name><name><surname>Yarychkivska</surname><given-names>O</given-names></name><name><surname>Boulard</surname><given-names>M</given-names></name><name><surname>Bestor</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>DNA methylation and DNA methyltransferases</article-title><source>Epigenetics &amp; Chromatin</source><volume>10</volume><elocation-id>23</elocation-id><pub-id pub-id-type="doi">10.1186/s13072-017-0130-8</pub-id><pub-id pub-id-type="pmid">28503201</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elbatrawy</surname><given-names>AA</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Nam</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>O-GlcNAcase: Emerging Mechanism, Substrate Recognition and Small-Molecule Inhibitors</article-title><source>ChemMedChem</source><volume>15</volume><fpage>1244</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1002/cmdc.202000077</pub-id><pub-id pub-id-type="pmid">32496638</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Etchegaray</surname><given-names>JP</given-names></name><name><surname>Mostoslavsky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Interplay between Metabolism and Epigenetics: A Nuclear Adaptation to Environmental Changes</article-title><source>Molecular Cell</source><volume>62</volume><fpage>695</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.05.029</pub-id><pub-id pub-id-type="pmid">27259202</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>JD</given-names></name><name><surname>Zamudio-Hurtado</surname><given-names>A</given-names></name><name><surname>Clawson</surname><given-names>H</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Salama</surname><given-names>SR</given-names></name><name><surname>Haeussler</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The UCSC repeat browser allows discovery and visualization of evolutionary conflict across repeat families</article-title><source>Mobile DNA</source><volume>11</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.1186/s13100-020-00208-w</pub-id><pub-id pub-id-type="pmid">32266012</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franson</surname><given-names>JJ</given-names></name><name><surname>Grose</surname><given-names>JH</given-names></name><name><surname>Larson</surname><given-names>KW</given-names></name><name><surname>Bridgewater</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gut Microbiota Regulates the Interaction between Diet and Genetics to Influence Glucose Tolerance</article-title><source>Medicines</source><volume>8</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.3390/medicines8070034</pub-id><pub-id pub-id-type="pmid">34357150</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Shao</surname><given-names>C</given-names></name><name><surname>Yan</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the Î³-globin gene in Î²-thalassemia</article-title><source>Blood</source><volume>137</volume><fpage>1652</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1182/blood.2020006425</pub-id><pub-id pub-id-type="pmid">33227819</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinez</surname><given-names>C</given-names></name><name><surname>Filhoulaud</surname><given-names>G</given-names></name><name><surname>Rayah-Benhamed</surname><given-names>F</given-names></name><name><surname>Marmier</surname><given-names>S</given-names></name><name><surname>Dubuquoy</surname><given-names>C</given-names></name><name><surname>Dentin</surname><given-names>R</given-names></name><name><surname>Moldes</surname><given-names>M</given-names></name><name><surname>Burnol</surname><given-names>AF</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Lefebvre</surname><given-names>T</given-names></name><name><surname>Girard</surname><given-names>J</given-names></name><name><surname>Postic</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver</article-title><source>Diabetes</source><volume>60</volume><fpage>1399</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.2337/db10-0452</pub-id><pub-id pub-id-type="pmid">21471514</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>RS</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Sandstrom</surname><given-names>R</given-names></name><name><surname>Canfield</surname><given-names>TK</given-names></name><name><surname>Thurman</surname><given-names>RE</given-names></name><name><surname>Weaver</surname><given-names>M</given-names></name><name><surname>Dorschner</surname><given-names>MO</given-names></name><name><surname>Gartler</surname><given-names>SM</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Sequencing newly replicated DNA reveals widespread plasticity in human replication timing</article-title><source>PNAS</source><volume>107</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1073/pnas.0912402107</pub-id><pub-id pub-id-type="pmid">19966280</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>HardivillÃ©</surname><given-names>S</given-names></name><name><surname>Banerjee</surname><given-names>PS</given-names></name><name><surname>Selen Alpergin</surname><given-names>ES</given-names></name><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Talbot</surname><given-names>CC</given-names></name><name><surname>Hu</surname><given-names>P</given-names></name><name><surname>Wolfgang</surname><given-names>MJ</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TATA-Box Binding Protein O-GlcNAcylation at T114 Regulates Formation of the B-TFIID Complex and Is Critical for Metabolic Gene Regulation</article-title><source>Molecular Cell</source><volume>77</volume><fpage>1143</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.11.022</pub-id><pub-id pub-id-type="pmid">31866147</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>GW</given-names></name><name><surname>Kreppel</surname><given-names>LK</given-names></name><name><surname>Comer</surname><given-names>FI</given-names></name><name><surname>Arnold</surname><given-names>CS</given-names></name><name><surname>Snow</surname><given-names>DM</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>DellaManna</surname><given-names>D</given-names></name><name><surname>Caine</surname><given-names>DS</given-names></name><name><surname>Earles</surname><given-names>BJ</given-names></name><name><surname>Akimoto</surname><given-names>Y</given-names></name><name><surname>Cole</surname><given-names>RN</given-names></name><name><surname>Hayes</surname><given-names>BK</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>O-GlcNAcylation of key nuclear and cytoskeletal proteins: reciprocity with O-phosphorylation and putative roles in protein multimerization</article-title><source>Glycobiology</source><volume>6</volume><fpage>711</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1093/glycob/6.7.711</pub-id><pub-id pub-id-type="pmid">8953283</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>GW</given-names></name><name><surname>Housley</surname><given-names>MP</given-names></name><name><surname>Slawson</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins</article-title><source>Nature</source><volume>446</volume><fpage>1017</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1038/nature05815</pub-id><pub-id pub-id-type="pmid">17460662</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Jing</surname><given-names>Y</given-names></name><name><surname>Agani</surname><given-names>F</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Carpenter</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>XR</given-names></name><name><surname>Peiper</surname><given-names>SS</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>LZ</given-names></name><name><surname>Jiang</surname><given-names>BH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation</article-title><source>EMBO Reports</source><volume>13</volume><fpage>1116</fpage><lpage>1122</lpage><pub-id pub-id-type="doi">10.1038/embor.2012.162</pub-id><pub-id pub-id-type="pmid">23146892</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imbeault</surname><given-names>M</given-names></name><name><surname>Helleboid</surname><given-names>PY</given-names></name><name><surname>Trono</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>KRAB zinc-finger proteins contribute to the evolution of gene regulatory networks</article-title><source>Nature</source><volume>543</volume><fpage>550</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1038/nature21683</pub-id><pub-id pub-id-type="pmid">28273063</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>R</given-names></name><name><surname>Katsura</surname><given-names>S</given-names></name><name><surname>Shimada</surname><given-names>H</given-names></name><name><surname>Tsuchiya</surname><given-names>H</given-names></name><name><surname>Hada</surname><given-names>M</given-names></name><name><surname>Okumura</surname><given-names>T</given-names></name><name><surname>Sugawara</surname><given-names>A</given-names></name><name><surname>Yokoyama</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TET3-OGT interaction increases the stability and the presence of OGT in chromatin</article-title><source>Genes to Cells</source><volume>19</volume><fpage>52</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/gtc.12107</pub-id><pub-id pub-id-type="pmid">24304661</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>R</given-names></name><name><surname>Wijesinghe</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Halsall</surname><given-names>J</given-names></name><name><surname>Liloglou</surname><given-names>T</given-names></name><name><surname>Kanhere</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A long intergenic non-coding RNA regulates nuclear localization of DNA methyl transferase-1</article-title><source>iScience</source><volume>24</volume><elocation-id>102273</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102273</pub-id><pub-id pub-id-type="pmid">33851096</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kao</surname><given-names>HJ</given-names></name><name><surname>Huang</surname><given-names>CH</given-names></name><name><surname>BretaÃ±a</surname><given-names>NA</given-names></name><name><surname>Lu</surname><given-names>CT</given-names></name><name><surname>Huang</surname><given-names>KY</given-names></name><name><surname>Weng</surname><given-names>SL</given-names></name><name><surname>Lee</surname><given-names>TY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A two-layered machine learning method to identify protein O-GlcNAcylation sites with O-GlcNAc transferase substrate motifs</article-title><source>BMC Bioinformatics</source><volume>16 Suppl 18</volume><elocation-id>S10</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-16-S18-S10</pub-id><pub-id pub-id-type="pmid">26680539</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>WJ</given-names></name><name><surname>Zweig</surname><given-names>AS</given-names></name><name><surname>Barber</surname><given-names>G</given-names></name><name><surname>Hinrichs</surname><given-names>AS</given-names></name><name><surname>Karolchik</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>BigWig and BigBed: enabling browsing of large distributed datasets</article-title><source>Bioinformatics</source><volume>26</volume><fpage>2204</fpage><lpage>2207</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btq351</pub-id><pub-id pub-id-type="pmid">20639541</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koobotse</surname><given-names>MO</given-names></name><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Holly</surname><given-names>JMP</given-names></name><name><surname>Perks</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Glucose Concentration in Cell Culture Medium Influences the BRCA1-Mediated Regulation of the Lipogenic Action of IGF-I in Breast Cancer Cells</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>8674</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21228674</pub-id><pub-id pub-id-type="pmid">33212987</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Trac</surname><given-names>C</given-names></name><name><surname>Kato</surname><given-names>H</given-names></name><name><surname>Costello</surname><given-names>KR</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Schones</surname><given-names>DE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>LTRs activated by Epstein-Barr virus-induced transformation of B cells alter the transcriptome</article-title><source>Genome Research</source><volume>28</volume><fpage>1791</fpage><lpage>1798</lpage><pub-id pub-id-type="doi">10.1101/gr.233585.117</pub-id><pub-id pub-id-type="pmid">30381291</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Rauch</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>ZX</given-names></name><name><surname>SzabÃ³</surname><given-names>PE</given-names></name><name><surname>Riggs</surname><given-names>AD</given-names></name><name><surname>Pfeifer</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>19489</fpage><lpage>19500</lpage><pub-id pub-id-type="doi">10.1074/jbc.M513249200</pub-id><pub-id pub-id-type="pmid">16682412</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Salz</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>KD</given-names></name><name><surname>Feinberg</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver</article-title><source>Genome Research</source><volume>26</volume><fpage>1730</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.1101/gr.211854.116</pub-id><pub-id pub-id-type="pmid">27737935</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Birol</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Minimap2: pairwise alignment for nucleotide sequences</article-title><source>Bioinformatics</source><volume>34</volume><fpage>3094</fpage><lpage>3100</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bty191</pub-id><pub-id pub-id-type="pmid">29750242</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberti</surname><given-names>MV</given-names></name><name><surname>Locasale</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Warburg Effect: How Does it Benefit Cancer Cells?</article-title><source>Trends in Biochemical Sciences</source><volume>41</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2015.12.001</pub-id><pub-id pub-id-type="pmid">26778478</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>RÃ¶nn</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epigenetics in Human Obesity and Type 2 Diabetes</article-title><source>Cell Metabolism</source><volume>29</volume><fpage>1028</fpage><lpage>1044</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.03.009</pub-id><pub-id pub-id-type="pmid">30982733</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lister</surname><given-names>R</given-names></name><name><surname>Pelizzola</surname><given-names>M</given-names></name><name><surname>Dowen</surname><given-names>RH</given-names></name><name><surname>Hawkins</surname><given-names>RD</given-names></name><name><surname>Hon</surname><given-names>G</given-names></name><name><surname>Tonti-Filippini</surname><given-names>J</given-names></name><name><surname>Nery</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>Z</given-names></name><name><surname>Ngo</surname><given-names>QM</given-names></name><name><surname>Edsall</surname><given-names>L</given-names></name><name><surname>Antosiewicz-Bourget</surname><given-names>J</given-names></name><name><surname>Stewart</surname><given-names>R</given-names></name><name><surname>Ruotti</surname><given-names>V</given-names></name><name><surname>Millar</surname><given-names>AH</given-names></name><name><surname>Thomson</surname><given-names>JA</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Ecker</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Human DNA methylomes at base resolution show widespread epigenomic differences</article-title><source>Nature</source><volume>462</volume><fpage>315</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1038/nature08514</pub-id><pub-id pub-id-type="pmid">19829295</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loman</surname><given-names>NJ</given-names></name><name><surname>Quick</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>JT</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A complete bacterial genome assembled de novo using only nanopore sequencing data</article-title><source>Nature Methods</source><volume>12</volume><fpage>733</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3444</pub-id><pub-id pub-id-type="pmid">26076426</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>O-GlcNAcylation: an important post-translational modification and a potential therapeutic target for cancer therapy</article-title><source>Molecular Medicine</source><volume>28</volume><elocation-id>115</elocation-id><pub-id pub-id-type="doi">10.1186/s10020-022-00544-y</pub-id><pub-id pub-id-type="pmid">36104770</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maresca</surname><given-names>A</given-names></name><name><surname>Zaffagnini</surname><given-names>M</given-names></name><name><surname>Caporali</surname><given-names>L</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Zanna</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>DNA methyltransferase 1 mutations and mitochondrial pathology: is mtDNA methylated?</article-title><source>Frontiers in Genetics</source><volume>6</volume><elocation-id>90</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2015.00090</pub-id><pub-id pub-id-type="pmid">25815005</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>SES</given-names></name><name><surname>Tan</surname><given-names>ZW</given-names></name><name><surname>Itkonen</surname><given-names>HM</given-names></name><name><surname>Duveau</surname><given-names>DY</given-names></name><name><surname>Paulo</surname><given-names>JA</given-names></name><name><surname>Janetzko</surname><given-names>J</given-names></name><name><surname>Boutz</surname><given-names>PL</given-names></name><name><surname>TÃ¶rk</surname><given-names>L</given-names></name><name><surname>Moss</surname><given-names>FA</given-names></name><name><surname>Thomas</surname><given-names>CJ</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Lazarus</surname><given-names>MB</given-names></name><name><surname>Walker</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors</article-title><source>Journal of the American Chemical Society</source><volume>140</volume><fpage>13542</fpage><lpage>13545</lpage><pub-id pub-id-type="doi">10.1021/jacs.8b07328</pub-id><pub-id pub-id-type="pmid">30285435</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Na</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Kang</surname><given-names>BJ</given-names></name><name><surname>Han</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Baik</surname><given-names>JH</given-names></name><name><surname>Swiatek-de Lange</surname><given-names>M</given-names></name><name><surname>Karl</surname><given-names>J</given-names></name><name><surname>Paik</surname><given-names>YK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Potential Regulatory Role of Human-Carboxylesterase-1 Glycosylation in Liver Cancer Cell Growth</article-title><source>Journal of Proteome Research</source><volume>19</volume><fpage>4867</fpage><lpage>4883</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.0c00787</pub-id><pub-id pub-id-type="pmid">33206527</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>OâHagan</surname><given-names>HM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sen</surname><given-names>S</given-names></name><name><surname>Destefano Shields</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Zhang</surname><given-names>YW</given-names></name><name><surname>Clements</surname><given-names>EG</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Van Neste</surname><given-names>L</given-names></name><name><surname>Easwaran</surname><given-names>H</given-names></name><name><surname>Casero</surname><given-names>RA</given-names></name><name><surname>Sears</surname><given-names>CL</given-names></name><name><surname>Baylin</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands</article-title><source>Cancer Cell</source><volume>20</volume><fpage>606</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.09.012</pub-id><pub-id pub-id-type="pmid">22094255</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perelman</surname><given-names>P</given-names></name><name><surname>Johnson</surname><given-names>WE</given-names></name><name><surname>Roos</surname><given-names>C</given-names></name><name><surname>SeuÃ¡nez</surname><given-names>HN</given-names></name><name><surname>Horvath</surname><given-names>JE</given-names></name><name><surname>Moreira</surname><given-names>MAM</given-names></name><name><surname>Kessing</surname><given-names>B</given-names></name><name><surname>Pontius</surname><given-names>J</given-names></name><name><surname>Roelke</surname><given-names>M</given-names></name><name><surname>Rumpler</surname><given-names>Y</given-names></name><name><surname>Schneider</surname><given-names>MPC</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>OâBrien</surname><given-names>SJ</given-names></name><name><surname>Pecon-Slattery</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A molecular phylogeny of living primates</article-title><source>PLOS Genetics</source><volume>7</volume><elocation-id>e1001342</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1001342</pub-id><pub-id pub-id-type="pmid">21436896</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structural Basis of DNMT1 and DNMT3A-Mediated DNA Methylation</article-title><source>Genes</source><volume>9</volume><elocation-id>620</elocation-id><pub-id pub-id-type="doi">10.3390/genes9120620</pub-id><pub-id pub-id-type="pmid">30544982</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rexach</surname><given-names>JE</given-names></name><name><surname>Clark</surname><given-names>PM</given-names></name><name><surname>Mason</surname><given-names>DE</given-names></name><name><surname>Neve</surname><given-names>RL</given-names></name><name><surname>Peters</surname><given-names>EC</given-names></name><name><surname>Hsieh-Wilson</surname><given-names>LC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Dynamic O-GlcNAc modification regulates CREB-mediated gene expression and memory formation</article-title><source>Nature Chemical Biology</source><volume>8</volume><fpage>253</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1038/nchembio.770</pub-id><pub-id pub-id-type="pmid">22267118</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rowe</surname><given-names>LA</given-names></name><name><surname>Degtyareva</surname><given-names>N</given-names></name><name><surname>Doetsch</surname><given-names>PW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>DNA damage-induced reactive oxygen species (ROS) stress response in <italic>Saccharomyces cerevisiae</italic></article-title><source>Free Radical Biology &amp; Medicine</source><volume>45</volume><fpage>1167</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2008.07.018</pub-id><pub-id pub-id-type="pmid">18708137</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Ewing</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications</article-title><source>Acta Biochimica et Biophysica Sinica</source><volume>46</volume><fpage>199</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmt146</pub-id><pub-id pub-id-type="pmid">24389641</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>HG</given-names></name><name><surname>Kim</surname><given-names>HB</given-names></name><name><surname>Kang</surname><given-names>MJ</given-names></name><name><surname>Ryum</surname><given-names>JH</given-names></name><name><surname>Yi</surname><given-names>EC</given-names></name><name><surname>Cho</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of the nuclear localisation signal of O-GlcNAc transferase and its nuclear import regulation</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>34614</elocation-id><pub-id pub-id-type="doi">10.1038/srep34614</pub-id><pub-id pub-id-type="pmid">27713473</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>FT</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Goodell</surname><given-names>MA</given-names></name><name><surname>Wan</surname><given-names>M</given-names></name><name><surname>Songyang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Ten-eleven translocation 1 (Tet1) is regulated by O-linked N-acetylglucosamine transferase (Ogt) for target gene repression in mouse embryonic stem cells</article-title><source>The Journal of Biological Chemistry</source><volume>288</volume><fpage>20776</fpage><lpage>20784</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.460386</pub-id><pub-id pub-id-type="pmid">23729667</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Cha</surname><given-names>HJ</given-names></name><name><surname>Na</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Cho</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Kim</surname><given-names>EK</given-names></name><name><surname>Kang</surname><given-names>CM</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Paik</surname><given-names>YK</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>O</italic>-GlcNAcylation of the Tumor Suppressor FOXO3 Triggers Aberrant Cancer Cell Growth</article-title><source>Cancer Research</source><volume>78</volume><fpage>1214</fpage><lpage>1224</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-3512</pub-id><pub-id pub-id-type="pmid">29301793</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname><given-names>H</given-names></name><name><surname>Cha</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Na</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>CY</given-names></name><name><surname>Han</surname><given-names>DH</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Paik</surname><given-names>YK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of ALDH6A1 as a Potential Molecular Signature in Hepatocellular Carcinoma via Quantitative Profiling of the Mitochondrial Proteome</article-title><source>Journal of Proteome Research</source><volume>19</volume><fpage>1684</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.9b00846</pub-id><pub-id pub-id-type="pmid">31985234</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sievers</surname><given-names>F</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Dineen</surname><given-names>D</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Karplus</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>McWilliam</surname><given-names>H</given-names></name><name><surname>Remmert</surname><given-names>M</given-names></name><name><surname>SÃ¶ding</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>JD</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega</article-title><source>Molecular Systems Biology</source><volume>7</volume><elocation-id>539</elocation-id><pub-id pub-id-type="doi">10.1038/msb.2011.75</pub-id><pub-id pub-id-type="pmid">21988835</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slawson</surname><given-names>C</given-names></name><name><surname>Copeland</surname><given-names>RJ</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>O-GlcNAc signaling: a metabolic link between diabetes and cancer?</article-title><source>Trends in Biochemical Sciences</source><volume>35</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2010.04.005</pub-id><pub-id pub-id-type="pmid">20466550</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Smit</surname><given-names>A</given-names></name><name><surname>R.</surname><given-names>H</given-names></name><name><surname>Green</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RepeatMasker</article-title><ext-link ext-link-type="uri" xlink:href="https://www.repeatmasker.org/">https://www.repeatmasker.org/</ext-link><date-in-citation iso-8601-date="2019-01-23">January 23, 2019</date-in-citation></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storer</surname><given-names>J</given-names></name><name><surname>Hubley</surname><given-names>R</given-names></name><name><surname>Rosen</surname><given-names>J</given-names></name><name><surname>Wheeler</surname><given-names>TJ</given-names></name><name><surname>Smit</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The Dfam community resource of transposable element families, sequence models, and genome annotations</article-title><source>Mobile DNA</source><volume>12</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s13100-020-00230-y</pub-id><pub-id pub-id-type="pmid">33436076</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Sriram</surname><given-names>K</given-names></name><name><surname>Qi</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>FM</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>CH</given-names></name><name><surname>Hsu</surname><given-names>CY</given-names></name><name><surname>Peterson</surname><given-names>KL</given-names></name><name><surname>Van Keuren-Jensen</surname><given-names>K</given-names></name><name><surname>Fueger</surname><given-names>PT</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Natarajan</surname><given-names>R</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>ZB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Suppression of Endothelial AGO1 Promotes Adipose Tissue Browning and Improves Metabolic Dysfunction</article-title><source>Circulation</source><volume>142</volume><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.041231</pub-id><pub-id pub-id-type="pmid">32393053</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thurman</surname><given-names>RE</given-names></name><name><surname>Day</surname><given-names>N</given-names></name><name><surname>Noble</surname><given-names>WS</given-names></name><name><surname>Stamatoyannopoulos</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Identification of higher-order functional domains in the human ENCODE regions</article-title><source>Genome Research</source><volume>17</volume><fpage>917</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1101/gr.6081407</pub-id><pub-id pub-id-type="pmid">17568007</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torres</surname><given-names>CR</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc</article-title><source>The Journal of Biological Chemistry</source><volume>259</volume><fpage>3308</fpage><lpage>3317</lpage><pub-id pub-id-type="pmid">6421821</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>UniProt</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>UniProt: the Universal Protein Knowledgebase in 2023</article-title><source>Nucleic Acids Research</source><volume>51</volume><fpage>D523</fpage><lpage>D531</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac1052</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaidyanathan</surname><given-names>K</given-names></name><name><surname>Durning</surname><given-names>S</given-names></name><name><surname>Wells</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology</article-title><source>Critical Reviews in Biochemistry and Molecular Biology</source><volume>49</volume><fpage>140</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.3109/10409238.2014.884535</pub-id><pub-id pub-id-type="pmid">24524620</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Understanding the Warburg effect: the metabolic requirements of cell proliferation</article-title><source>Science</source><volume>324</volume><fpage>1029</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1126/science.1160809</pub-id><pub-id pub-id-type="pmid">19460998</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vasconcelos-Dos-Santos</surname><given-names>A</given-names></name><name><surname>de Queiroz</surname><given-names>RM</given-names></name><name><surname>da Costa Rodrigues</surname><given-names>B</given-names></name><name><surname>Todeschini</surname><given-names>AR</given-names></name><name><surname>Dias</surname><given-names>WB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression</article-title><source>Journal of Bioenergetics and Biomembranes</source><volume>50</volume><fpage>175</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1007/s10863-017-9740-x</pub-id><pub-id pub-id-type="pmid">29322286</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walgren</surname><given-names>JLE</given-names></name><name><surname>Vincent</surname><given-names>TS</given-names></name><name><surname>Schey</surname><given-names>KL</given-names></name><name><surname>Buse</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>High glucose and insulin promote O-GlcNAc modification of proteins, including alpha-tubulin</article-title><source>American Journal of Physiology. Endocrinology and Metabolism</source><volume>284</volume><fpage>E424</fpage><lpage>E434</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00382.2002</pub-id><pub-id pub-id-type="pmid">12397027</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Pandak</surname><given-names>WM</given-names></name><name><surname>Heuman</surname><given-names>D</given-names></name><name><surname>Hylemon</surname><given-names>PB</given-names></name><name><surname>Ren</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High Glucose Induces Lipid Accumulation via 25-Hydroxycholesterol DNA-CpG Methylation</article-title><source>iScience</source><volume>23</volume><elocation-id>101102</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2020.101102</pub-id><pub-id pub-id-type="pmid">32408171</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname><given-names>L</given-names></name><name><surname>Vosseller</surname><given-names>K</given-names></name><name><surname>Hart</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc</article-title><source>Science</source><volume>291</volume><fpage>2376</fpage><lpage>2378</lpage><pub-id pub-id-type="doi">10.1126/science.1058714</pub-id><pub-id pub-id-type="pmid">11269319</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>WH</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Nam</surname><given-names>HW</given-names></name><name><surname>Ju</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Cho</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability</article-title><source>Nature Cell Biology</source><volume>8</volume><fpage>1074</fpage><lpage>1083</lpage><pub-id pub-id-type="doi">10.1038/ncb1470</pub-id><pub-id pub-id-type="pmid">16964247</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>AQ</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Chi</surname><given-names>L</given-names></name><name><surname>Ye</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Validation, Identification, and Biological Consequences of the Site-specific <italic>O</italic>-GlcNAcylation Dynamics of Carbohydrate-responsive Element-binding Protein (ChREBP)</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>16</volume><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1074/mcp.M116.061416</pub-id><pub-id pub-id-type="pmid">28450420</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Qian</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Protein O-GlcNAcylation: emerging mechanisms and functions</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>452</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nrm.2017.22</pub-id><pub-id pub-id-type="pmid">28488703</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>MD</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>W</given-names></name><name><surname>Ong</surname><given-names>Q</given-names></name><name><surname>Mi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>O-GlcNAc transferase inhibits visceral fat lipolysis and promotes diet-induced obesity</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>181</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13914-8</pub-id><pub-id pub-id-type="pmid">31924761</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yarychkivska</surname><given-names>O</given-names></name><name><surname>Shahabuddin</surname><given-names>Z</given-names></name><name><surname>Comfort</surname><given-names>N</given-names></name><name><surname>Boulard</surname><given-names>M</given-names></name><name><surname>Bestor</surname><given-names>TH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>BAH domains and a histone-like motif in DNA methyltransferase 1 (DNMT1) regulate <italic>de novo</italic> and maintenance methylation <italic>in vivo</italic></article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>19466</fpage><lpage>19475</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.004612</pub-id><pub-id pub-id-type="pmid">30341171</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yompakdee</surname><given-names>C</given-names></name><name><surname>Bun-ya</surname><given-names>M</given-names></name><name><surname>Shikata</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>N</given-names></name><name><surname>Harashima</surname><given-names>S</given-names></name><name><surname>Oshima</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>A putative new membrane protein, Pho86p, in the inorganic phosphate uptake system of <italic>Saccharomyces cerevisiae</italic></article-title><source>Gene</source><volume>171</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(96)00079-0</pub-id><pub-id pub-id-type="pmid">8675028</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Bowe</surname><given-names>DB</given-names></name><name><surname>Paterson</surname><given-names>AJ</given-names></name><name><surname>Kudlow</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>O-GlcNAc modification is an endogenous inhibitor of the proteasome</article-title><source>Cell</source><volume>115</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(03)00974-7</pub-id><pub-id pub-id-type="pmid">14675536</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked Î²-N-acetylglucosamine transferase (OGT)</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>5986</fpage><lpage>5996</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.524140</pub-id><pub-id pub-id-type="pmid">24394411</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Di Palma</surname><given-names>S</given-names></name><name><surname>Preisinger</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>M</given-names></name><name><surname>Polat</surname><given-names>AN</given-names></name><name><surname>Heck</surname><given-names>AJR</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Toward a comprehensive characterization of a human cancer cell phosphoproteome</article-title><source>Journal of Proteome Research</source><volume>12</volume><fpage>260</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1021/pr300630k</pub-id><pub-id pub-id-type="pmid">23186163</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Dinh</surname><given-names>HQ</given-names></name><name><surname>Ramjan</surname><given-names>Z</given-names></name><name><surname>Weisenberger</surname><given-names>DJ</given-names></name><name><surname>Nicolet</surname><given-names>CM</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Berman</surname><given-names>BP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>DNA methylation loss in late-replicating domains is linked to mitotic cell division</article-title><source>Nature Genetics</source><volume>50</volume><fpage>591</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41588-018-0073-4</pub-id><pub-id pub-id-type="pmid">29610480</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Liang</surname><given-names>G</given-names></name><name><surname>Molloy</surname><given-names>PL</given-names></name><name><surname>Jones</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>DNA methylation enables transposable element-driven genome expansion</article-title><source>PNAS</source><volume>117</volume><fpage>19359</fpage><lpage>19366</lpage><pub-id pub-id-type="doi">10.1073/pnas.1921719117</pub-id><pub-id pub-id-type="pmid">32719115</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85595.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.11.491514" link-type="continued-by" xlink:href="https://sciety.org/articles/10.1101/2022.05.11.491514"/></front-stub><body><p>In this study Shin and colleagues investigate the role of the posttranslational modification of the DNA methyltransferase by covalent linkage of the N-Acetylglucosamine (O-GlcNAc). The authors present compelling evidence showing that a prolonged high fat/sucrose diet causes global protein O-GlcNAcylation in the liver and DNMT1 is among the proteins that increase their O-GlcNAc level. This result is significant because of the paucity of in vivo data addressing the interplay between metabolism and protein O-GlcNAcylation. The paper also shows that DNMT1's O-GlcNAcylation level correlated to extracellular glucose levels in other cell types.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85595.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Isales</surname><given-names>Carlos</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/012mef835</institution-id><institution>Augusta University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Boulard</surname><given-names>Matthieu</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yr73893</institution-id><institution>European Molecular Biology Laboratory</institution></institution-wrap><country>Italy</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/10.1101/2022.05.11.491514">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.11.491514v6">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Inhibition of DNMT1 methyltransferase activity via glucose-regulated O-GlcNAcylation alters the epigenome&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by Carlos Isales as the Senior and Reviewing Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Matthieu Boulard (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) It would be very interesting to analyse the conservation of the DNMT1 O-GlcNAc sites and perhaps include the relevant protein alignment in Figure 2.</p><p>2) I fail to understand the reason to display the predicted sites of O-GlcNAcylation that were not confirmed experimentally.</p><p>3) It would be informative to mention the previously reported sites of phosphorylation of DNMT1.</p><p>4) Molecular weight should be indicated on western blots.</p><p>5) p-value/statistics are missing in Figure 4-supplement 3.</p><p>6) Figure 3E shows that treatment of cells with 25 mM glucose + TMG causes a substantial loss of DNA methylation at LINE1 elements (about a 20% decrease). Figure 3 sup 2 shows the result of the digestion of gDNA by the methyl-sensitive enzyme HpaII. While the demethylation in 5-aza treated cells is clear, the global methylation level cells cultured in presence of 25mM glucose + TMG is comparable to that of the control (C2), in contradiction with the Figure 3E that shows important demethylation in 25mM glucose + TMG condition. The discrepancy suggests to me that the global DNA methylation LINE-1 kit may not be very reliable.</p><p>7) Figure 4A actually shows a substantial loss of methylation in DNMT1-S878A mutant (CTRL) as compared to WT (CTRL), again suggesting that the global DNA methylation LINE-1 kit may not be very reliable.</p><p>8) The DNMT1 inhibitor used, namely 5-azacytidine has notorious cytotoxicity. Recently a new inhibitor developed by GlaxoSmithKline (e.g. GSK-3484862) was shown to be more effective with minimal non-specific toxicity and is therefore recommended (https://doi.org/10.1186/s13072-021-00429-0).</p><p>9) Figure 4âfigure supplement 6: The evolutionary age should be made more explicit in the figure.</p><p>10) DNA methylation heat maps (Figure 5âfigure supplement 1). The unit should be indicated on the color scheme (5mCpG/CpG).</p><p>11) As pointed out in the public review, the effect of TMG should be also tested in physiological glucose conditions.</p><p>12) The causal findings are based on a model of hyper-O-GlcNAcylation that increases O-GlcNAc on DNMT1 and also impacts many other proteins. It would be complementary to study the phenotype of the S878A mutation on endogenous DNMT1. Because S878 can also be phosphorylated, the result would inform on the regulatory function of S878 (via O-GlcNAc or phosphorylation).</p><p>13) An alternative approach to the induction of O-GlcNAcylation by TMG treatment is the genetic substitution S-&gt;C mutation that creates a thio-linked GlcNAc (S-GlcNAc), which is a non-hydrolyzable O-GlcNAc analog. https://www.nature.com/articles/s41594-019-0325-8</p><p>This trick could enable the study of the phenotype of hyperglycosylated DNMT1 more specifically (as TMG may have side effects and impact a large number of GlcNAc sites).</p><p>14) About &quot;Here, we report that the activity of DNMT1 is regulated by extracellular levels of glucose through O-GlcNAcylation, resulting in loss of methylation within PMDs.&quot; (lines 54-56). The use of the word &quot;resulting&quot; is an overstatement because it is unknown whether a high glucose level causes loss of DNA methylation (the data shows that the combination of high glucose and OGA inhibitor causes loss of methylation but it remains to be tested if that's true with high glucose alone).</p><p>15) It would be interesting to speculate in the discussion on the possible mechanism of regulation of DNMT1 activity by S878-O-GlcNAc.</p><p>16) Quality and representation of the data</p><p>Many of the graphs are incorrectly labeled. It is incorrect to say &quot;relative expression OglcNac/DNMT1&quot; as in Figure 1A or 1B. The correct term is &quot;relative abundance&quot;. It is definitely wrong to say &quot;Relative expression (Cell death)&quot; as in Figure 5C.</p><p>(17) Many of the graphs (eg 1A) have three dots for WT, all at value 1. I understand their value was set to 1. They also have 3 dots in the experimental condition. Typically, the variability is extremely small, making me think these are technical replicates with the same sample, instead of biological replicates. Also, which experimental point goes with which control?</p><p>(18) None of the IP experiments show inputs. I found this surprising at best, and misleading at worst.</p><p>(19) The assays for measuring DNMT activity are mostly ELISA assays. One has to look quite hard outside of the paper to understand how these assays work. For instance: does the DNMT1 Elisa assay start with hemimethylated DNA? This is critical for interpretation, but the information is not provided.</p><p>(20) The authors would do well to complement the ELISA assays with orthogonal methods such as LC-MS, enzymatic digestions, or others.</p><p>(21) Limitations of the experimental system</p><p>A large proportion of the conclusions are derived from the overexpression of DNMT1 (WT or mutant forms) in cell lines. Never are we shown or large or small the overexpression level is, even though it could be a major source of artifacts. It is clear that a better experimental solution would be a CRISPR knock-in mutation of S878A. Transient overexpression feels quite outdated.</p><p>(22) Overinterpretation</p><p>I feel that many conclusions are not solidly proven. For instance, we do not know for absolutely sure that OGlcNacylation of S878 decreases activity, as this position can also be phosphorylated. A more convincing experiment would be to purify the recombinant enzyme, OglcNac it in vitro, and test the activity in vitro.</p><p>(23) The most speculative part of the data is the last. Do the authors suggest that high glucose causes high OglcNac on DNMT1, causes low activity, causes gene misexpression, and causes ROS and apoptosis? How can we rule out that, instead, high glucose causes ROS, which causes apoptosis, which messes up DNA methylation artifactually?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85595.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) It would be very interesting to analyse the conservation of the DNMT1 O-GlcNAc sites and perhaps include the relevant protein alignment in Figure 2.</p></disp-quote><p>We thank the reviewers for suggesting this. In the revised manuscript we have compared the conservation of the DNMT1 <italic>O</italic>-GlcNAc sites between vertebrates. The modification site of human DNMT1 (S878) is conserved among vertebrates.Â We have included this in the revised manuscript (see page 6 and Figure 2B).</p><disp-quote content-type="editor-comment"><p>2) I fail to understand the reason to display the predicted sites of O-GlcNAcylation that were not confirmed experimentally.</p></disp-quote><p>In the revised manuscript we have updated this figure to show only the <italic>O</italic>-GlcNAcylated and phosphorylated sites of DNMT1 detected in this study. Several of the residues of DNMT1 that we found phosphorylated were recently added to the PRIDE database â those were also removed from the revised manuscript (see page 6 and Figure 2B).</p><disp-quote content-type="editor-comment"><p>3) It would be informative to mention the previously reported sites of phosphorylation of DNMT1.</p></disp-quote><p>There are 26 reported phosphorylated sites within DNMT1 (S35, S127, S133, T137, S141, S143, S152, S154, T166, S189, S192, S294, S312, S394, S398, Y399, S509, S549, S714, S732, S878, S953, S954, Y969, S1105, and S1122).Â The previously unreported phosphorylated sites that we have identified are T208, S209, and S1122. This information has been included in a new Supplemental Table (Table S3).</p><disp-quote content-type="editor-comment"><p>4) Molecular weight should be indicated on western blots.</p></disp-quote><p>We have added the molecular weight of western blots to all figures in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5) p-value/statistics are missing in Figure 4-supplement 3.</p></disp-quote><p>We apologize for this oversight. This has been corrected in the revised manuscript. This figure is now Figure 4âfigure supplement 4.</p><disp-quote content-type="editor-comment"><p>6) Figure 3E shows that treatment of cells with 25 mM glucose + TMG causes a substantial loss of DNA methylation at LINE1 elements (about a 20% decrease). Figure 3 sup 2 shows the result of the digestion of gDNA by the methyl-sensitive enzyme HpaII. While the demethylation in 5-aza treated cells is clear, the global methylation level cells cultured in presence of 25mM glucose + TMG is comparable to that of the control (C2), in contradiction with the Figure 3E that shows important demethylation in 25mM glucose + TMG condition. The discrepancy suggests to me that the global DNA methylation LINE-1 kit may not be very reliable.</p></disp-quote><p>We apologize for not making this clear in the initial submission. We have now detailed the observed difference in genomic DNA methylation levels between the LINE-1 kit and HpaII digestion/gel separation of genomic DNA â to state they both have similar trends in loss of DNA in the revised manuscript but the observed differences may be due to the differences in digestions between MspI and HpaII. The analysis from direct sequencing utilizing the PromethION has also shown loss of DNA methylation at LINE elements suggesting our overall conclusion that loss of DNA methylation generally occurs is valid (Figure 4 âfigure supplement 4). We have moved Figure 3E toÂ Figure 3âfigure supplement 2A.</p><disp-quote content-type="editor-comment"><p>7) Figure 4A actually shows a substantial loss of methylation in DNMT1-S878A mutant (CTRL) as compared to WT (CTRL), again suggesting that the global DNA methylation LINE-1 kit may not be very reliable.</p></disp-quote><p>As indicated above, the revised manuscript includes a more detailed explanation.</p><disp-quote content-type="editor-comment"><p>8) The DNMT1 inhibitor used, namely 5-azacytidine has notorious cytotoxicity. Recently a new inhibitor developed by GlaxoSmithKline (e.g. GSK-3484862) was shown to be more effective with minimal non-specific toxicity and is therefore recommended (https://doi.org/10.1186/s13072-021-00429-0).</p></disp-quote><p>We thank the reviewer for this suggestion. We have utilized this inhibitor in the revised manuscript alongside the 5-aza analysis (Figure3âfigure supplement 2A ; Figure 5 âfigure supplement 4).</p><disp-quote content-type="editor-comment"><p>9) Figure 4âfigure supplement 6: The evolutionary age should be made more explicit in the figure.</p></disp-quote><p>We added evolutionary distance with the age of each group. The evolutionary distance between each group is from Perelman et al., PLoS Genet 2011.</p><p>Perelman, P., Johnson, W.E., Roos, C., Seuanez, H.N., Horvath, J.E., Moreira, M.A., Kessing, B., Pontius, J., Roelke, M., Rumpler, Y., et al. (2011). A molecular phylogeny of living primates. PLoS Genet 7, e1001342.</p><disp-quote content-type="editor-comment"><p>10) DNA methylation heat maps (Figure 5âfigure supplement 1). The unit should be indicated on the color scheme (5mCpG/CpG).</p></disp-quote><p>We apologize for this oversight. We have corrected this in the revised manuscript (Figure 4D and Figure 5âfigure supplement 1).</p><disp-quote content-type="editor-comment"><p>11) As pointed out in the public review, the effect of TMG should be also tested in physiological glucose conditions.</p></disp-quote><p>We thank the reviewers for suggesting these analyses to strengthen the manuscript. The physiological glucose levels are between 5 to 7 mM, and 25mM is in hyperglycemic range, which corresponds to severe diabetes. The new Figure 1A shows TMG treatment with physiological glucose conditions.Â We have included new WB data of 5mM glucose, 5mM glucose + TMG, 25mM glucose, and 25mM glucose + TMG (Figure 1A).</p><disp-quote content-type="editor-comment"><p>12) The causal findings are based on a model of hyper-O-GlcNAcylation that increases O-GlcNAc on DNMT1 and also impacts many other proteins. It would be complementary to study the phenotype of the S878A mutation on endogenous DNMT1. Because S878 can also be phosphorylated, the result would inform on the regulatory function of S878 (via O-GlcNAc or phosphorylation).</p></disp-quote><p>We have toned down the language throughout the revised manuscript. We demonstrated <italic>O</italic>-GlcNAcylation of DNMT1 using IP/WB and mass spec analysis. An alanine mutation was performed to block the posttranslational modification of serine (Hardwick et al., 1986). In addition, it was demonstrated that the DNA methyltransferase activity of DNMT1 due to phospho-S878 was not affected through the use of S878D (May et al., 1998).Â The DNMT1 activity assay in Figure3D utilized only the myc-tagged recombinant DNMT1. Through this it was verified that the activity of DNMT1 decreased only in the high glucose + Thiamet-G treated condition. We have furthermore revised Figure 3âfigure supplement 3A, B using DNMT1-S878D to verify that phosphorylation of DNMT1 within S878 does not affect DNA methyltransferase activity.</p><p>Hardwick, J.M., Shaw, K.E., Wills, J.W., and Hunter, E. (1986). Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol 103, 829-838.</p><p>May, G.H., Allen, K.E., Clark, W., Funk, M., and Gillespie, D.A. (1998). Analysis of the interaction between c-Jun and c-Jun N-terminal kinase in vivo. J Biol Chem 273, 33429-33435.</p><disp-quote content-type="editor-comment"><p>13) An alternative approach to the induction of O-GlcNAcylation by TMG treatment is the genetic substitution S-&gt;C mutation that creates a thio-linked GlcNAc (S-GlcNAc), which is a non-hydrolyzable O-GlcNAc analog. <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/s41594-019-0325-8">https://www.nature.com/articles/s41594-019-0325-8</ext-link>. This trick could enable the study of the phenotype of hyperglycosylated DNMT1 more specifically (as TMG may have side effects and impact a large number of GlcNAc sites).</p></disp-quote><p>We thank the reviewer for this interesting suggestion. As indicated, side effects may exist because TMG impacts proteins globally. The current project is focused on the change in the function of DNMT1 according to the presence or absence of <italic>O</italic>-GlcNAc in S878 by the change in glucose level. In other words, after blocking other external factors in normal and hyperglycemic conditions, only the post-translational modification of DNMT1 is changed and then its function is determined, which is considered to be of sufficient value in terms of protein function change. Also, as shown in Figure 4A, the substitution of one amino acid in DNMT1 could cause a slight decrease in the DNA methyltransferase function of DNMT1. Considering this, substitution with cysteine could also affect DNMT1. This is indeed an interesting avenue of study and one we intend to follow up on in future work.</p><disp-quote content-type="editor-comment"><p>14) About &quot;Here, we report that the activity of DNMT1 is regulated by extracellular levels of glucose through O-GlcNAcylation, resulting in loss of methylation within PMDs.&quot; (lines 54-56). The use of the word &quot;resulting&quot; is an overstatement because it is unknown whether a high glucose level causes loss of DNA methylation (the data shows that the combination of high glucose and OGA inhibitor causes loss of methylation but it remains to be tested if that's true with high glucose alone).</p></disp-quote><p>We have toned down the language throughout the revised manuscript.</p><disp-quote content-type="editor-comment"><p>15) It would be interesting to speculate in the discussion on the possible mechanism of regulation of DNMT1 activity by S878-O-GlcNAc.</p></disp-quote><p>We have included discussion on possible mechanisms of regulation of DNMT1 activity in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>16) Quality and representation of the data</p><p>Many of the graphs are incorrectly labeled. It is incorrect to say &quot;relative expression OglcNac/DNMT1&quot; as in Figure 1A or 1B. The correct term is &quot;relative abundance&quot;. It is definitely wrong to say &quot;Relative expression (Cell death)&quot; as in Figure 5C.</p></disp-quote><p>We apologize for these oversights. They have been resolved in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(17) Many of the graphs (eg 1A) have three dots for WT, all at value 1. I understand their value was set to 1. They also have 3 dots in the experimental condition. Typically, the variability is extremely small, making me think these are technical replicates with the same sample, instead of biological replicates. Also, which experimental point goes with which control?</p></disp-quote><p>We thank the reviewer for the suggestion. Most of our experiments were performed in 3 biological replicates. For ease of viewing, each control was set to 1 (for example, 5 mM low glucose treated Hep3B cells in Figure 1A). However, the display has been changed to show more information in the revised manuscript. We furthermore provided more details to the text to indicate these are biological replicates (page 24).</p><disp-quote content-type="editor-comment"><p>(18) None of the IP experiments show inputs. I found this surprising at best, and misleading at worst.</p></disp-quote><p>We apologize for this oversight. We have included these controls in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>(19) The assays for measuring DNMT activity are mostly ELISA assays. One has to look quite hard outside of the paper to understand how these assays work. For instance: does the DNMT1 Elisa assay start with hemimethylated DNA? This is critical for interpretation, but the information is not provided.</p></disp-quote><p>We thank the reviewer for the suggestion. We included more details in the Methods in the revised manuscript (page 20).</p><disp-quote content-type="editor-comment"><p>(20) The authors would do well to complement the ELISA assays with orthogonal methods such as LC-MS, enzymatic digestions, or others.</p></disp-quote><p>We thank the reviewer for the suggestion. As the reviewer pointed out, for Figure 3 and Figure 5B, ELISA methods were performed. In the case of measuring the DNA methyltransferase activity of Figure 3, we examined several different kits for measuring methyltransferase activity, but all of them were ELISA based. Measurement of oxidative DNA damage using 8-OHdG in Figure 5B was further bolstered with fluorescence data using Î³H2A.X.</p><disp-quote content-type="editor-comment"><p>(21) Limitations of the experimental system</p><p>A large proportion of the conclusions are derived from the overexpression of DNMT1 (WT or mutant forms) in cell lines. Never are we shown or large or small the overexpression level is, even though it could be a major source of artifacts. It is clear that a better experimental solution would be a CRISPR knock-in mutation of S878A. Transient overexpression feels quite outdated.</p></disp-quote><p>The mutation from serine to phenylalanine at amino acid S878 of DNMT1 was recently reported in Î²-thalassemia (Gong et al., 2021). This work demonstrates that the mutation abolishes the phosphorylation of DNMT1, resulting in low stability and loss of catalytic activity. This indicates that damage to the S878 site of DNMT1 inhibits DNA methyltransferase activity. As shown in Figure 4A, there is a slight loss of methylation in the S878A mutant despite the low glucose concentration, indicating a potential compromise of function for the overexpressed protein. The CRISPR knock-in experiments are a great suggestion but are not without their own potential sources of error. In particular, using CRISPR/Cas9 in the field of <italic>O</italic>-GlcNAc research can be challenging. For example, it has been reported that sugar modifications caused by microscopic protein structural changes can change the aggregation behavior of the protein Î±-synuclein (Moon et al., 2022; Galesic et al., 2021). This is something we intend to pursue in follow up work.</p><p>Gong, Y., Zhang, X., Zhang, Q., Zhang, Y., Ye, Y., Yu, W., Shao, C., Yan, T., Huang, J., Zhong, J., et al. (2021). A natural DNMT1 mutation elevates the fetal hemoglobin level via epigenetic derepression of the Î³-globin gene in Î²-thalassemia. Blood <italic>137</italic>, 1652-1657.</p><p>Moon, S.P., Javed, A., Hard, E.R., and Pratt, M.R. (2022). Methods for Studying Site-Specific O-GlcNAc Modifications: Successes, Limitations, and Important Future Goals. JACS Au 2, 74-83.</p><p>Galesic, A., Rakshit, A., Cutolo, G., Pacheco, R.P., Balana, A.T., Moon, S.P., and Pratt, M.R. (2021). Comparison of N-Acetyl-Glucosamine to Other Monosaccharides Reveals Structural Differences for the Inhibition of Î±-Synuclein Aggregation. ACS Chem Biol 16, 14-19.</p><disp-quote content-type="editor-comment"><p>(22) Overinterpretation</p><p>I feel that many conclusions are not solidly proven. For instance, we do not know for absolutely sure that OGlcNacylation of S878 decreases activity, as this position can also be phosphorylated. A more convincing experiment would be to purify the recombinant enzyme, OglcNac it in vitro, and test the activity in vitro.</p></disp-quote><p>We have toned down the language throughout the revised manuscript. Our finding with the DNMT1-S878D mutant (Figure 3D), demonstrates that the DNA methyltransferase activity of DNMT1 due to phospho-S878 mimetic does that recapture the effects of DNMT1-S878A. (Hardwick et al., 1986; May et al., 1998).</p><p>Hardwick, J.M., Shaw, K.E., Wills, J.W., and Hunter, E. (1986). Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol 103, 829-838.</p><p>May, G.H., Allen, K.E., Clark, W., Funk, M., and Gillespie, D.A. (1998). Analysis of the interaction between c-Jun and c-Jun N-terminal kinase in vivo. J Biol Chem 273, 33429-33435.</p><disp-quote content-type="editor-comment"><p>(23) The most speculative part of the data is the last. Do the authors suggest that high glucose causes high OglcNac on DNMT1, causes low activity, causes gene misexpression, and causes ROS and apoptosis? How can we rule out that, instead, high glucose causes ROS, which causes apoptosis, which messes up DNA methylation artifactually?</p></disp-quote><p>We thank the reviewer for the suggestion. According to our results, DNMT1-S878A mutant suppressed the observed DNA damage and cell death due to high glucose/TMG treatment suggesting that elevated DNMT1 <italic>O</italic>-GlcNAcylation and subsequent reduction in its activity influences DNA damage and cell death. To supplement this observation, we have now included additional experiments with GSK-3484862 showing that loss of DNMT1 activity can increase DNA damage. We have further toned down language with regards to these results.</p></body></sub-article></article>